Document:

EX-4.1

 Exhibit 4.1 

EXECUTION VERSION 

AMENDMENT NO. 13 

AMENDMENT NO. 13 TO THE CREDIT AGREEMENT, dated as of December 7, 2020 (this “Amendment”), among THE
SHERWIN-WILLIAMS COMPANY, an Ohio corporation (the “Company”), the Lenders party hereto, CITICORP USA, INC. (“CUSA”), as Administrative Agent (in such capacity, the “Administrative
Agent”), and CUSA, as Issuing Bank (in such capacity, the “Issuing Bank”). Capitalized terms not otherwise defined in this Amendment have the same meanings as specified in the Credit Agreement referred to below.

 PRELIMINARY STATEMENTS: 

(1) The Company, the Administrative Agent, the Lenders from time to time party thereto and the Issuing Bank are parties to that certain Credit
Agreement, dated as of May 9, 2016 (as amended by Amendment No. 1 to the Credit Agreement, dated as of May 12, 2016, Amendment No. 2 to the Credit Agreement, dated as of June 20, 2016, Amendment No. 3 to the Credit
Agreement, dated as of August 1, 2016, Amendment No. 4 to the Credit Agreement, dated as of January 31, 2017, Amendment No. 5 to the Credit Agreement, dated as of February 13, 2017, Amendment No. 6 to the Credit
Agreement, dated as of February 27, 2017, Amendment No. 7 to the Credit Agreement, dated as of May 8, 2017, Amendment No. 8 to the Credit Agreement, dated as of May 11, 2017, Amendment No. 9 to the Credit Agreement,
dated as of February 27, 2018, Amendment No. 10 to the Credit Agreement, dated as of July 26, 2018, Amendment No. 11 to the Credit Agreement, dated as of September 14, 2020, and Amendment No. 12 to the Credit Agreement,
dated as of November 9, 2020, the “Existing Credit Agreement”; the Existing Credit Agreement as amended by this Amendment, the “Credit Agreement”). 

(2) The Company has requested, and the Administrative Agent and the Lenders have agreed, on the terms and conditions set forth herein, to amend
the Existing Credit Agreement as specified herein. 
 NOW, THEREFORE, in consideration of the premises and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows: 
 SECTION 1.
Amendments to the Existing Credit Agreement. Upon, and subject to, the satisfaction or waiver in accordance with Section 9.02 of the Existing Credit Agreement of the conditions precedent set forth in Section 2 below, the Existing
Credit Agreement is hereby amended as follows: 
 (a) The following new definition is included in Section 1.01 of the
Existing Credit Agreement in the proper alphabetical order as follows: 
 ““Amendment
No. 13 Effective Date” means December 7, 2020.” 
 (b) Each of the
following definitions in Section 1.01 of the Existing Credit Agreement is hereby amended and restated in its entirety as follows: 
  

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	1	  	Amendment No. 13 to Credit Agreement

 ““Commitment” means, with respect to each
Lender, the commitment of such Lender to acquire participations in the Letter of Credit and to make Loans, as such commitment may be (a) reduced from time to time pursuant to Section 2.07, (b) reduced or increased from time to time
pursuant to assignments by or to such Lender pursuant to Section 9.04 or (c) reduced or increased from time to time pursuant to an amendment hereto. The amount of each Lender’s Commitment on the Amendment No. 13 Effective Date is
set forth on Schedule 2.01, or in the Assignment and Acceptance pursuant to which such Lender shall have assumed its Commitment, as applicable.” 

““Maturity Date” means December 20, 2021; provided, however, that (i) with
respect to the Commitments in the aggregate amount of $150,000,000, the Maturity Date shall mean December 20, 2021, (ii) with respect to the Commitments in the aggregate amount of $150,000,000, the Maturity Date shall mean June 20, 2022,
(iii) with respect to the Commitments in the aggregate amount of $250,000,000, the Maturity Date shall mean December 20, 2022, (iv) with respect to the Commitments in the aggregate amount of $125,000,000, the Maturity Date shall mean
June 20, 2023, (v) with respect to the Commitments in the aggregate amount of $75,000,000, the Maturity Date shall mean June 20, 2025, and (vi) with respect to the Commitments in the aggregate amount of $125,000,000, the Maturity Date
shall mean December 20, 2025.” 
 (c) Schedule 2.01 of the Existing Credit Agreement is hereby amended and restated in its entirety
as set forth in Schedule 2.01 attached hereto. 
 SECTION 2. Conditions of Effectiveness. This Amendment shall become effective on
the date (the “Amendment No. 13 Effective Date”) on which: 
 (a) the Administrative
Agent shall have received a counterpart signature page of this Amendment duly executed by (i) the Company, (ii) the Administrative Agent, (iii) the Lenders, and (iv) the Issuing Bank or, as to any of the foregoing parties,
written evidence reasonably satisfactory to the Administrative Agent that such party has executed this Amendment; 
 (b) the Administrative
Agent shall have received one or more counterparts of the Fee Letter Amendment No. 13, dated as of the date hereof, duly executed by the Company and Citicorp USA, Inc.; and 

(c) the representations and warranties set forth in Section 4 of this Amendment shall be true and correct in all respects. 

SECTION 3. Effect of this Amendment, Etc. 

(a) Except as expressly set forth herein, this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of, or
otherwise affect the rights and remedies of the Issuing Bank, the Lenders or the Administrative Agent under the Credit Agreement or any other Loan Document, and shall not alter, modify, amend or in any way affect any of the terms, conditions,
obligations, covenants or agreements contained in the Credit Agreement or any other Loan Document, all of which are ratified and affirmed in all respects and shall continue in full force and effect. 

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	2	  	Amendment No. 13 to Credit Agreement

 (b) Nothing herein shall be deemed to entitle the Company to a consent to, or a waiver,
amendment, modification or other change of, any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other Loan Document in similar or different circumstances. 

(c) After the Amendment No. 13 Effective Date, each reference in any Loan Document to the Credit Agreement, to “this Agreement”,
“hereunder”, “hereof” or words of like import referring to the Credit Agreement, shall mean and be a reference to the Existing Credit Agreement, as modified hereby. This Amendment shall constitute a “Loan Document” for
all purposes of the Credit Agreement and the other Loan Documents. 
 SECTION 4. Representations and Warranties. The Company
represents and warrants to the Administrative Agent and the Lenders that, on and as of the date hereof and on and as of the Amendment No. 13 Effective Date: 

(a) (i) The execution, delivery and performance by the Company of this Amendment and the transactions contemplated hereby have been duly
authorized by all necessary corporate action, and (ii) this Amendment has been duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with
its terms, except as may be limited by applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or similar laws of general applicability relating to or affecting creditors’ rights generally and subject to general
principals of equity, regardless of whether considered in a proceeding in equity or at law. 
 (b) The representations and warranties of the
Company contained in the Credit Agreement and any other Loan Document are true and correct in all material respects, except to the extent such representations and warranties expressly relate to an earlier date (in which case such representations and
warranties are true and correct in all material respects as of such earlier date). 
 (c) Both before and after giving effect to this
Amendment, no Default or Event of Default has occurred and is continuing. 
 SECTION 5. Execution in Counterparts. This Amendment may
be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.
Delivery by telecopier or other form of electronic communication of an executed counterpart of a signature page to this Amendment shall be effective as delivery of an original executed counterpart of this Amendment, it being understood and agreed
that the words “execution,” “signed,” “signature,” and words of similar import in, or with respect to, any Loan Document shall be deemed to include electronic signatures or the keeping of records in electronic form
(including, without limitation, the execution by means of “DocuSign”, or other similar platform or service approved by the Administrative Agent), each of which shall be of the same effect, validity and enforceability as manually executed
signatures or 

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	3	  	Amendment No. 13 to Credit Agreement

 
a paper-based recordkeeping system, as the case may be, to the extent and as provided for under applicable law, including the Electronic Signatures in Global and National Commerce Act of 2000 (15
USC § 7001 et seq.), the Electronic Signatures and Records Act of 1999 (NY State Technology Law §§ 301-309), or any other similar state laws based on the Uniform Electronic Transactions Act;
provided, that any electronic signature delivered by means of “DocuSign”, or other similar third-party platform by one party shall be promptly followed by an email attestation by such party to the recipient party confirming that
such electronic signature so delivered is the signature of such party; provided, further, that upon the request of the Administrative Agent, any electronic signature shall be followed by a manually executed counterpart as promptly as
reasonably practicable. 
 SECTION 6. Governing Law. This Amendment shall be governed by, and construed in accordance with, the laws
of the State of New York. 
 SECTION 7. WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AMENDMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH
PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND
(B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 

SECTION 8. Jurisdiction; Consent to Service of Process. 

(a) The Company hereby irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of the Supreme
Court of the State of New York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action or proceeding arising out of or relating
to this Amendment, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such
New York State or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the
judgment or in any other manner provided by law. Nothing in this Amendment shall affect any right that the Administrative Agent or any Lender or the Issuing Bank may otherwise have to bring any action or proceeding relating to this Amendment against
the Company or its properties in the courts of any jurisdiction. 
 (b) The Company hereby irrevocably and unconditionally waives, to the
fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Amendment in any court referred to in
subsection (b) of this Section. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	4	  	Amendment No. 13 to Credit Agreement

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by
their respective officers thereunto duly authorized, as of the date first above written. 
  

			
	THE SHERWIN-WILLIAMS COMPANY
		
	By:	 	 /s/ Jeffrey J. Miklich

		 	Name: Jeffrey J. Miklich
		 	Title:   Vice President and Treasurer

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  		  	Amendment No. 13 to Credit Agreement

 
			
	 CITICORP USA, INC.,
 as
Administrative Agent and as Issuing Bank

		
	By:	 	 /s/ David Jaffe

		 	Name: David Jaffe
		 	Title:   Authorized Signer

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  		  	Amendment No. 13 to Credit Agreement

 
			
	 CITIBANK, N.A.,
 as
Lender

		
	By:	 	 /s/ John Chun

		 	Name: John Chun
		 	Title:   Vice President

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  		  	Amendment No. 13 to Credit Agreement

 Schedule 2.01 

Commitments 
  

	 	A.	 For the period ending on December 20, 2021: 

 

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	875,000,000	 
		  	  
	  
	 
	 Total
	  	$	875,000,000	 
		  	  
	  
	 

  

	 	B.	 For the period from and including December 21, 2021 to and including June 20, 2022:

  

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	725,000,000	 
		  	  
	  
	 
	 Total
	  	$	725,000,000	 
		  	  
	  
	 

  

	 	C.	 For the period from and including June 21, 2022 to and including December 20, 2022:

  

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	575,000,000	 
		  	  
	  
	 
	 Total
	  	$	575,000,000	 
		  	  
	  
	 

  

	 	D.	 For the period from and including December 21, 2022 to and including June 20, 2023:

  

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	325,000,000	 
		  	  
	  
	 
	 Total
	  	$	325,000,000	 
		  	  
	  
	 

  

	 	E.	 For the period from and including June 21, 2023 to and including June 20, 2025:

  

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	200,000,000	 
		  	  
	  
	 
	 Total
	  	$	200,000,000	 
		  	  
	  
	 

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	Schedule 2.01 – 1	  	Amendment No. 13 to Credit Agreement

	 	F.	 For the period from and including June 21, 2025 to and including December 20, 2025:

  

					
	 Lender
	  	Commitment	 
	 Citibank, N.A.
	  	$	125,000,000	 
		  	  
	  
	 
	 Total
	  	$	125,000,000	 
		  	  
	  
	 

  

					
		  		  	THE SHERWIN-WILLIAMS COMPANY
		  	Schedule 2.01 – 2	  	Amendment No. 13 to Credit AgreementExhibit 10.1

 

SEPARATION AND DISTRIBUTION AGREEMENT

 

By and Between NEUROTROPE, INC.

 

and

 

NEUROTROPE BIOSCIENCE, INC.

 

Dated as of December 6, 2020

 

     

     

    

 

TABLE OF CONTENTS

 

	 	Page
	 	 
	ARTICLE I  Definitions	2
	ARTICLE II  The Separation	12
	SECTION 2.01	 	Transfer of Assets and Assumption of Liabilities	12
	SECTION 2.02	 	Certain Matters Governed Exclusively by Ancillary Agreements	13
	SECTION 2.03	 	Termination of Agreements	13
	SECTION 2.04	 	Shared Contracts	14
	SECTION 2.05	 	Disclaimer of Representations and Warranties	15
	SECTION 2.06	 	Allocation of Welfare Benefit Claims	15
	SECTION 2.07	 	Workers’ Compensation Claims	15
	SECTION 2.08	 	Reimbursement by NBI	16
	ARTICLE III  Actions Pending the Distribution	16
	SECTION 3.01	 	Actions Prior to the Distribution	16
	SECTION 3.02	 	Conditions Precedent to Consummation of the Distribution	18
	ARTICLE IV  The Distribution	19
	SECTION 4.01	 	The Distribution	19
	SECTION 4.02	 	Fractional Shares	19
	SECTION 4.03	 	Sole Discretion of Neurotrope	20
	ARTICLE V  Mutual Releases; Indemnification	20
	SECTION 5.01	 	Release of Pre-Distribution Claims	20
	SECTION 5.02	 	Indemnification by NBI	22
	SECTION 5.03	 	Indemnification by Neurotrope	22
	SECTION 5.04	 	Indemnification Obligations Net of Insurance Proceeds and Third-Party Proceeds	22
	SECTION 5.05	 	Procedures for Indemnification of Third-Party Claims	23
	SECTION 5.06	 	Additional Matters	24
	SECTION 5.07	 	Remedies Cumulative	25
	SECTION 5.08	 	Survival of Indemnities	25
	SECTION 5.09	 	Limitation on Liability	25
	ARTICLE VI  Access to Information; Confidentiality	26
	SECTION 6.01	 	Agreement for Exchange of Information; Archives	26
	SECTION 6.02	 	Ownership of Information	27
	SECTION 6.03	 	Compensation for Providing Information	27

 

     ii

     

    

 

	SECTION 6.04	 	Record Retention	27
	SECTION 6.05	 	Accounting Information	27
	SECTION 6.06	 	Limitations of Liability	28
	SECTION 6.07	 	Production of Witnesses; Records; Cooperation	29
	SECTION 6.08	 	Confidential Information	29
	ARTICLE VII  Insurance	30
	SECTION 7.01	 	Insurance	30
	ARTICLE VIII  Intellectual Property	33
	SECTION 8.01	 	Consent To Use Trademarks And Duty To Cooperate	33
	SECTION 8.02	 	Domain Names	35
	SECTION 8.03	 	Scope	35
	SECTION 8.04	 	Licenses; Assignments	35
	ARTICLE IV  Further Assurances and Additional Covenants	35
	SECTION 9.01	 	Further Assurances	35
	ARTICLE X  Termination	36
	SECTION 10.01	 	Termination	36
	SECTION 10.02	 	Effect of Termination	36
	ARTICLE XI  Miscellaneous	37
	SECTION 11.01	 	Counterparts; Entire Agreement; Corporate Power	37
	SECTION 11.02	 	Governing Law; Jurisdiction	37
	SECTION 11.03	 	Assignability	37
	SECTION 11.04	 	Third-Party Beneficiaries	38
	SECTION 11.05	 	Notices	38
	SECTION 11.06	 	Severability	39
	SECTION 11.07	 	Publicity	39
	SECTION 11.08	 	Expenses	39
	SECTION 11.09	 	Headings	40
	SECTION 11.10	 	Survival of Covenants	40
	SECTION 11.11	 	Waivers of Default	40
	SECTION 11.12	 	Specific Performance	40
	SECTION 11.13	 	Amendments	40
	SECTION 11.14	 	Interpretation	40

 

     iii

     

    

 

Schedule I – Payables Transactions

Schedule II – Neurotrope Bioscience, Inc. Equity
Interests

Schedule III – Neurotrope, Inc. Retained Assets

Schedule IV – Neurotrope, Inc. Retained Liabilities

Schedule V – Surviving Intercompany Agreements
and Accounts

Schedule VI – Shared Contracts

Schedule VII – Neurotrope, Inc. Marks

Schedule VIII – Neurotrope Bioscience, Inc. Marks

Schedule IX – Neurotrope Bioscience, Inc. Domain
Names Held by Neurotrope Bioscience, Inc. to be Transferred to Neurotrope Bioscience, Inc. or its Affiliates

Schedule X – Neurotrope, Inc. Domain Names Held
by Neurotrope Bioscience, Inc. to be Transferred to Neurotrope, Inc. or its Affiliates or Agents

 

     iv

     

    

 

SEPARATION AND DISTRIBUTION
AGREEMENT, dated as of _______, 2020, by and between Neurotrope, Inc., a Nevada corporation (“Neurotrope”),
and Neurotrope Bioscience, Inc., a Delaware corporation (“NBI”). Capitalized terms used herein and not otherwise
defined in Article I shall have the respective meanings assigned to them in the Merger Agreement (as hereinafter defined).

 

R E C I T A L S

 

WHEREAS, Neurotrope,
Petros Pharmaceuticals, Inc.(“Petros”), PM Merger Sub 1, LLC (“Merger Sub 1”), PN Merger
Sub 2, Inc. (“Merger Sub 2”), and Metuchen Pharmaceuticals LLC (“Metuchen”) entered
into that certain Agreement and Plan of Merger dated as of May 17, 2020, as amended (the “Merger Agreement”)
under which the parites have agreed to (1) the merger of Merger Sub 1, with and into Metuchen, with Metuchen surviving as a wholly-owned
subsidiary of Petros (the “Metuchen Merger”) and (2) the merger of Merger Sub 2 with and into Neurotrope, with
Neurotrope surviving as a wholly-owned subsidiary of Petros (the “Neurotrope Merger” and together with the Metuchen
Merger, the “Merger”), and in connection therewith each outstanding share of Neurotrope common stock will be
exchanged for one (1) share of Petros common stock and each outstanding share of Neurotrope preferred stock will be exchanged for
one (1) share of Petros preferred stock.

 

WHEREAS the board of
directors of Neurotrope has determined that it is in the best interests of Neurotrope and its shareholders to distribute its entire
interest in its wholly owned Subsidiary, NBI, by way of a stock dividend to be made to holders of Neurotrope Common Stock;

 

WHEREAS in furtherance
of the foregoing, it is appropriate and desirable to effect the Spin-Off, as more fully described in this Agreement;

 

WHEREAS Neurotrope
and NBI have prepared, and NBI has filed with the Commission, the Form S-1 that sets forth appropriate disclosure concerning NBI
and the Distribution;

 

WHEREAS Neurotrope
and NBI intend that each of the transactions included in the Separation and Distribution qualify for its Intended Tax Treatment;
and

 

WHEREAS it is appropriate
and desirable to set forth the principal corporate transactions required to effect the Spin-Off and certain other agreements that
will govern certain matters relating to the Spin-Off and the relationship of Neurotrope, NBI and their respective Subsidiaries
following the Distribution.

 

NOW, THEREFORE, in
consideration of the mutual agreements, provisions and covenants contained in this Agreement, the Parties, intending to be legally
bound, hereby agree as follows:

 

     1

     

    

 

ARTICLE
I

 

Definitions

 

For the purposes of
this Agreement, the following terms shall have the following meanings:

 

“Action”
means any claim, demand, action, suit, countersuit, arbitration, inquiry, proceeding or investigation by or before any Governmental
Authority or any Federal, state, local, foreign or international arbitration or mediation tribunal.

 

“Affiliate”
of any Person means a Person that controls, is controlled by or is under common control with such Person. As used herein, “control”
of any entity means the possession, directly or indirectly, of the power to direct or cause the direction of the management or
policies of such entity, whether through ownership of voting securities or other interests, by contract or otherwise; provided,
however, that (i) NBI shall not be considered an Affiliate of Neurotrope or any of the other members of the Neurotrope Group
and (ii) Neurotrope and the other members of the Neurotrope Group shall not be considered Affiliates of NBI.

 

“Agent”
means the distribution agent to be appointed by Neurotrope to distribute to the Record Holders, pursuant to the Distribution, the
shares of NBI Common Stock held by Neurotrope.

 

“Agreement”
means this Separation and Distribution Agreement, including the Schedules hereto, as it may be amended from time to time.

 

“Ancillary
Agreements” means any instruments, assignments, documents and agreements executed in connection with the implementation
of the transactions contemplated by this Agreement.

 

“Assets”
means all assets, properties and rights (including goodwill), wherever located (including in the possession of vendors or other
third parties or elsewhere), whether real, personal or mixed, tangible or intangible, or accrued or contingent, in each case whether
or not recorded or reflected or required to be recorded or reflected on the books and records or financial statements of any Person,
including the following:

 

(a)            all
accounting and other books, records and files, whether in paper, microfilm, microfiche, computer tape or disc, magnetic tape or
any other form;

 

(b)            all
apparatus, computers and other electronic data processing equipment, fixtures, machinery, furniture, office and other equipment,
including hardware systems, circuits and other computer and telecommunication assets and equipment, special and general tools,
test devices, APIs and models and other tangible personal property;

 

(c)            all
inventories of APIs, raw materials, supplies, work-in-process and finished goods and products;

 

(d)            all
interests in real property of whatever nature, including easements, whether as owner, mortgagee or holder of a Security Interest
in real property, lessor, sublessor, lessee, sublessee or otherwise;

 

(e)            all
interests in any capital stock or other equity interests of NBI; all bonds, notes, debentures or other securities issued by NBI;
all loans, advances or other extensions of credit or capital contributions to NBI; all other investments in securities of NBI;
and all rights as a partner, joint venturer or participant;

 

    2

     

    

 

(f)             all
license agreements, leases of personal property, open purchase orders for raw materials, supplies, parts or services, unfilled
orders for the manufacture and sale of products and other contracts, agreements or commitments and all rights arising thereunder;

 

(g)            all written technical information, data, specifications, research and development information, engineering drawings,
operating and maintenance manuals and materials and analyses prepared by consultants and other third parties;

 

(h)            all
United States, state, multinational and foreign intellectual property, including patents, copyrights, trade names, trademarks,
service marks, slogans, logos, trade dresses and other source indicators and the goodwill of the business symbolized thereby;
all registrations, applications, recordings, disclosures, renewals, continuations, continuations-in-part, divisions, reissues,
reexaminations, foreign counterparts and other legal protections and rights related to any of the foregoing; mask works, trade
secrets, inventions and other proprietary information, including know-how, processes, formulae, techniques, technical data, designs,
drawings, specifications, customer and supplier lists, pricing and cost information and business and marketing plans and proposals,
discoveries, inventions, licenses from third parties granting the right to use any of the foregoing and all tangible embodiments
of the foregoing in whatever form or medium;

 

(i)             all
computer applications, programs, software and other code (in object and source code form), including operating software, network
software, firmware, middleware, design software, design tools, systems documentation, instructions, ASP, HTML, DHTML, SHTML and
XML files, cgi and other scripts, APIs, web widgets, algorithms, models, methodologies, files, documentation related to any of
the foregoing and all tangible embodiments of the foregoing in whatever form or medium now known or yet to be created;

 

(j)             all
Internet URLs, domain names, social media handles and Internet user names;

 

(k)            all
websites, databases, content, text, graphics, images, audio, video, data and other copyrightable works or other works of authorship
including all translations, adaptations, derivations and combinations thereof;

 

(l)             all
cost information, sales and pricing data, customer prospect lists, supplier records, customer and supplier lists, subscriber,
customer and vendor data, correspondence and lists, product literature and other advertising and promotional materials, artwork,
design, development and manufacturing files, vendor and customer drawings, formulations and specifications, server and traffic
logs, quality records and reports and other books, records, studies, surveys, reports, plans, business records and documents;

 

(m)           all
prepaid expenses, trade accounts and other accounts and notes receivable (whether current or non-current);

 

(n)            all
claims or rights against any Person arising from the ownership of any other Asset, all rights in connection with any bids or offers,
all claims, causes in action, lawsuits, judgments or similar rights, all rights under express or implied warranties, all rights
of recovery and all rights of setoff of any kind and demands of any nature, in each case whether accrued or contingent, whether
in tort, contract or otherwise and whether arising by way of counterclaim or otherwise;

 

    3

     

    

 

(o)            all
rights under insurance policies and all rights in the nature of insurance, indemnification or contribution;

 

(p)            all
licenses, permits, approvals and authorizations that have been issued by any Governmental Authority and all pending applications
therefor;

 

(q)            Cash,
bank accounts, lock boxes and other deposit arrangements;

 

(r)             interest
rate, currency, commodity or other swap, collar, cap or other hedging or similar agreements or arrangements; and

 

(s)            all
goodwill as a going concern and other intangible properties.

 

“Benefit Plan”
means any plan, program, policy, agreement, arrangement or understanding that is an employment, consulting, deferred compensation,
executive compensation, incentive bonus or other bonus, employee pension, profit sharing, savings, retirement, supplemental retirement,
stock option, stock purchase, stock appreciation right, restricted stock, restricted stock unit, deferred stock unit, other equity-based
compensation, severance pay, retention, change in control, salary continuation, life, death benefit, health, hospitalization, workers’
compensation, sick leave, vacation pay, disability or accident insurance or other employee benefit plan, program, agreement or
arrangement, including any “employee benefit plan” (as defined in Section 3(3) of ERISA) (whether or not subject
to ERISA) sponsored or maintained by such entity or to which such entity is a party.

 

“Cash”
means cash, cash equivalents, bank deposits and marketable securities, whether denominated in United States dollars or otherwise.

 

“Commission”
means the Securities and Exchange Commission.

 

“Consents”
means any consents, waivers or approvals from, or notification requirements to, any Person other than a member of either Group.

 

“Credit Support
Instruments” has the meaning set forth in Section 3.01(a).

 

“D&O Policies”
has the meaning set forth in Section 8.01(e).

 

“Determination”
has the meaning set forth in the TMA.

 

“Distribution”
means the distribution, on a pro rata basis, by Neurotrope to the Record Holders of all the outstanding shares of NBI Common Stock
owned by Neurotrope on the Distribution Date.

 

“Distribution
Date” means the date, determined by Neurotrope in accordance with Section 5.03, on which the Distribution occurs.

 

    4

     

    

 

“Domain Names”
means the domain names owned by a member of the Neurotrope Group or NBI, including those listed in Schedule IX, Schedule X or Schedule
XI.

 

“Employee”
means any individual employed by another Person.

 

“Establishment
Date” means the date on which the applicable NBI Benefit Plan was or will be established.

 

“First Post-Distribution
Report” has the meaning set forth in Section 12.07.

 

“Form S-1”
means the registration statement on Form S-1 filed by NBI with the Commission to effect the registration of NBI Common Stock pursuant
to the Securities Act in connection with the Distribution, as such registration statement may be amended or supplemented from time
to time.

 

“Former NBI
Employee” means, as of an applicable date, each individual who is a former Employee of NBI For purposes of this Agreement,
references to a “Former NBI Employee” shall not be deemed to refer to a Salary Continuation Former Employee, who shall
be addressed specifically where applicable.

 

“Governmental
Approvals” means any notices, reports or other filings to be given to or made with, or any Consents, registrations or
permits to be obtained from, any Governmental Authority.

 

“Governmental
Authority” means any federal, state, local, foreign or international court, government, department, commission, board,
bureau, agency, official or other legislative, judicial, regulatory, administrative or governmental authority.

 

“Group”
means the Neurotrope Group.

 

“Indemnifying
Party” has the meaning set forth in Section 6.04(a).

 

“Indemnitee”
has the meaning set forth in Section 6.04(a).

 

“Indemnity
Payment” has the meaning set forth in Section 6.04(a).

 

“Information”
means information, whether or not patentable, copyrightable or protectable as a trade secret, in written, oral, electronic or other
tangible or intangible forms, stored in any medium now known or yet to be created, including studies, reports, records, books,
contracts, instruments, surveys, discoveries, ideas, concepts, know-how, techniques, designs, specifications, drawings, blueprints,
diagrams, models, prototypes, samples, flow charts, data, computer data, disks, diskettes, tapes, computer programs or other software,
marketing plans, customer names, communications by or to attorneys (including attorney-client privileged communications), memos
and other materials prepared by attorneys or under their direction (including attorney work product) and other technical, financial,
employee or business information or data, documents, correspondence, materials and files.

 

    5

     

    

 

“Insurance
Proceeds” means those monies:

 

(a)            received by an insured (or its successor-in-interest) from an insurance carrier;

 

(b)           paid by an insurance carrier on behalf of the insured (or its successor-in-interest); or

 

(c)            received
(including by way of set-off) from any third party in the nature of insurance, contribution or indemnification in respect of any
Liability; in any such case net of any applicable premium adjustments (including reserves and retrospectively rated premium adjustments),
net of any costs or expenses incurred in the collection thereof and net of any Taxes resulting from the receipt thereof.

 

“Intended
Tax Treatment” has the meaning set forth in the TMA.

 

“Intercompany
Accounts” has the meaning set forth in Section 2.03(a).

 

“Intercompany
Agreements” has the meaning set forth in Section 2.03(a).

 

“Law”
means any statute, law, regulation, ordinance, rule, judgment, rule of common law, order, decree, government approval, concession,
grant, franchise, license, agreement, directive, guideline, policy, requirement or other governmental restriction or any similar
form of decision of, or determination by, or any interpretation or administration of any of the foregoing by, any Governmental
Authority, whether now or hereinafter in effect and, in each case, as amended.

 

“Liabilities”
means any and all claims, debts, demands, actions, causes of action, suits, damages, obligations, accruals, accounts payable, reckonings,
bonds, indemnities and similar obligations, agreements, promises, guarantees, make-whole agreements and similar obligations, and
other liabilities and requirements, including all contractual obligations, whether absolute or contingent, matured or unmatured,
liquidated or unliquidated, accrued or unaccrued, known or unknown, whenever arising, and including those arising under any Law,
Action, threatened or contemplated Action or any award of any arbitrator or mediator of any kind, and those arising under any contract,
commitment or undertaking, including those arising under this Agreement, in each case, whether or not recorded or reflected or
required to be recorded or reflected on the books and records or financial statements of any Person. For the avoidance of doubt,
Liabilities shall include attorneys’ fees, the costs and expenses of all assessments, judgments, settlements and compromises,
and any and all other costs and expenses whatsoever reasonably incurred in connection with anything contemplated by the preceding
sentence (including costs and expenses incurred in investigating, preparing or defending against any such Actions or threatened
or contemplated Actions).

 

“Litigation
Conditions” has the meaning set forth in Section 6.05(b).

 

“NBI”
has the meaning set forth in the preamble.

 

    6

     

    

 

“NBI Assets”
means, without duplication, the following Assets:

 

(a)            all
Assets held by NBI;

 

(b)            all
other equity, partnership, membership, joint venture and similar interests set forth on Schedule II under the caption “Joint
Ventures and Minority Investments”;

 

(c)            all
Assets reflected on the NBI Business Balance Sheet, and all Assets acquired after the date of the NBI Business Balance Sheet that,
had they been acquired on or before such date and owned as of such date, would have been reflected on the NBI Business Balance
Sheet if prepared in accordance with generally accepted accounting principles in effect in the United States (“GAAP”)
applied on a consistent basis, subject to any dispositions of such Assets subsequent to the date of the NBI Business Balance Sheet;

 

(d)            the
rights related to the NBI Portion of any Shared Contract;

 

(e)            all other Assets that are expressly provided by this Agreement or any Ancillary Agreement as Assets to be assigned
to or retained by, or allocated to, NBI;

 

(f)             all
Assets held by a member of the Neurotrope Group that are determined by Neurotrope, in good faith, to be primarily related to or
used or held for use primarily in connection with the business or operations of NBI; and

 

(g)            Excess
Cash (as defined in the Merger Agreement, as amended).

 

Notwithstanding the
foregoing, the NBI Assets shall not include (i) any Neurotrope Retained Assets, (ii) any Assets governed by the TMA, (iii) the
rights related to the Neurotrope Portion of Shared Contracts, and (iv) any Assets determined by Neurotrope, in good faith, to arise
primarily from the business or operations of the Neurotrope Business (unless otherwise expressly provided in this Agreement.

 

“NBI Business”
means the business currently conducted by NBI.

 

“NBI Business
Balance Sheet” means the balance sheet of the NBI Business, including the notes thereto, as of June 30, 2020, included
in the Form S-1.

 

“NBI Common
Stock” means the common stock, $0.0001 par value per share, of NBI.

 

“NBI Employee”
means, as of an applicable date, each Employee employed by NBI, including any individual who is on a leave of absence (including
short-term disability but excluding long-term disability) from which such Employee is permitted to return to active employment
in accordance with NBI’s personnel policies, but excluding any Former NBI Employee.

 

“NBI Entities”
means the entities the equity, partnership, membership, joint venture or similar interests of which are set forth on Schedule II
under the caption “Joint Ventures and Minority Investments”.

 

“NBI Indemnitees”
has the meaning set forth in Section 6.03.

 

    7

     

    

 

“NBI Liabilities”
means, without duplication, the following Liabilities:

 

(a)            all Liabilities of NBI and the NBI Entities;

 

(b)            all
Liabilities to the extent relating to, arising out of or resulting from:

 

(i)             the
operation or conduct of the NBI Business as conducted at any time prior to the Distribution (including any Liability to the extent
relating to, arising out of or resulting from any act or failure to act by any director, officer, employee, agent or representative
(whether or not such act or failure to act is or was within such Person’s authority), which act or failure to act relates
to the NBI Business);

 

(ii)            the
operation or conduct of the NBI Business or any other business conducted by NBI after the Distribution (including any Liability
relating to, arising out of or resulting from any act or failure to act by any director, officer, employee, agent or representative
(whether or not such act or failure to act is or was within such Person’s authority));

 

(iii)           any
terminated, divested or discontinued businesses or operations of the NBI Business; or

 

(iv)           the
NBI Assets;

 

(c)            all
Liabilities reflected as liabilities or obligations on the NBI Business Balance Sheet, and all Liabilities arising or assumed
after the date of the NBI Business Balance Sheet that, had they arisen or been assumed on or before such date and been existing
obligations as of such date, would have been reflected on the NBI Business Balance Sheet if prepared in accordance with GAAP applied
on a consistent basis, subject to any discharge of such Liabilities subsequent to the date of the NBI Business Balance Sheet;

 

(d)            the obligations related to the NBI Portion of any Shared Contract;

 

(e)            all
other Liabilities that are expressly provided by this Agreement or any Ancillary Agreement as Liabilities to be assumed or retained
by, or allocated to, NBI; and

 

(f)             all Liabilities to the extent relating to, arising out of or resulting from any untrue statement or alleged untrue
statement of a material fact or omission or alleged omission to state a material fact required to be stated therein or necessary
to make the statements therein not misleading, with respect to all information contained in, or incorporated by reference into,
the Form S-1 and any other documents filed with the Commission in connection with the Spin-Off or as contemplated by this Agreement,
other than with respect to the Neurotrope Disclosure Sections.

 

Notwithstanding the
foregoing, the NBI Liabilities shall not include (i) any Neurotrope Retained Liabilities, (ii) any Liabilities governed by the
TMA, (iii) any obligations related to the Neurotrope Portion of any Shared Contract or (iv) any Liabilities determined by Neurotrope,
in good faith, to be primarily related to the business or operations of the Neurotrope Business (unless otherwise expressly provided
in this Agreement).

 

    8

     

    

 

“NBI Marks”
means the trademarks, trade names and service marks owned by NBI and all goodwill relating thereto, including those listed in Schedule
VIII.

 

“NBI Portion”
has the meaning set forth in Section 2.04.

 

“NBI Welfare
Plan” means each Welfare Plan sponsored or maintained by NBI.

 

“Neurotrope”
has the meaning set forth in the preamble.

 

“Neurotrope
Assets” means (i) all Assets of the Neurotrope Group, (ii) the Neurotrope Retained Assets, (iii) any Assets held by NBI
determined by Neurotrope, in good faith, to be primarily related to or used primarily in connection with the business or operations
of the Neurotrope Business, (iv) all interests in the capital stock, or other equity interests in, the members of the Neurotrope
Group (other than Neurotrope ) and (v) the rights related to the Neurotrope Portion of any Shared Contract. Notwithstanding the
foregoing, the Neurotrope Assets shall not include (a) any Assets governed by the TMA, and (b) the NBI Assets.

 

“Neurotrope
Business” means the business and operations conducted by Neurotrope and its Subsidiaries other than the NBI Business.

 

“Neurotrope
Common Stock” means the common stock, $0.0001 par value per share, of Neurotrope.

 

“Neurotrope
Disclosure Sections” means all information set forth in or omitted from the Form S-1 to the extent relating to (a) the
Neurotrope Group, (b) the Neurotrope Liabilities, (c) the Neurotrope Assets or (d) the substantive disclosure set forth in the
Form S-1 relating to Neurotrope’s board of directors’ consideration of the Spin-Off, including the section entitled
 “Reasons for the Spin-Off”.

 

“Neurotrope
Group” means Neurotrope and each of its Subsidiaries, but excluding NBI.

 

“Neurotrope
Indemnitees” has the meaning set forth in Section 6.02.

 

“Neurotrope
Liabilities” means (i) all Liabilities of the Neurotrope Group, (ii) the Neurotrope Retained Liabilities, (iii) any obligations
related to the Neurotrope Portion of any Shared Contract or (iv) any Liabilities determined by Neurotrope, in good faith, to be
primarily related to the business or operations of the Neurotrope Business (unless otherwise expressly provided in this Agreement).
Notwithstanding the foregoing, the Neurotrope Liabilities shall not include (a) any Liabilities governed by the TMA or (b) the
NBI Liabilities.

 

“Neurotrope
Marks” means the trademarks, trade names and service marks containing Neurotrope, Inc. or the abbreviations of Neurotrope
owned by a member of the Neurotrope Group and all goodwill relating thereto, including those listed in Schedule VII.

 

“Neurotrope
Portion” has the meaning set forth in Section 2.04.

 

“Neurotrope
Retained Assets” means the Assets to be retained by the Neurotrope Group set forth on Schedule IIII.

 

    9

     

    

 

“Neurotrope
Retained Liabilities” means the Liabilities to be retained by the Neurotrope Group set forth on Schedule IV.

 

“Neurotrope
Welfare Plan” means each Welfare Plan sponsored or maintained by a member of the Neurotrope Group.

 

“Party”
means either party hereto, and “Parties” means both parties hereto.

 

“Payables
Transactions” means the intercompany payables transactions set forth on Schedule II to be settled as set forth on Schedule
I.

 

“Person”
means an individual, a general or limited partnership, a corporation, a trust, a joint venture, an unincorporated organization,
a limited liability company, any other entity and any Governmental Authority.

 

“Pre-Separation
Claims-Based Insurance Claim” means any claim made against NBI or Neurotrope Group and reported to the applicable insurer(s)
on or prior to the Distribution Date in respect of a wrongful act or omission occurring on or prior to the Distribution Date that
results in a Liability under a “claims-made-based” insurance policy of the Neurotrope Group in effect on or prior to
the Distribution Date or any extended reporting period thereof.

 

“Pre-Separation
Insurance Claim” means a (i) Pre-Separation Claims-Based Insurance Claim or (ii) Action (whether made prior to, on or
following the Distribution Date) in respect of a Liability occurring on or prior to the Distribution Date under an “occurrence-based”
insurance policy of any member of the Neurotrope Group in effect on or prior to the Distribution Date.

 

“Record Date”
means the close of business on the date to be determined by the Neurotrope board of directors as the record date for determining
the shares of Neurotrope Common Stock in respect of which shares of NBI Common Stock will be distributed pursuant to the Distribution.

 

“Record Holders”
has the meaning set forth in Section 5.01(b).

 

“Retained
Information” has the meaning set forth in Section 7.04.

 

“Salary Continuation
Former Employee” means any former NBI Employee who was employed by NBI or a Subsidiary of NBI immediately prior to termination
of his or her employment, is receiving salary continuation severance payments or separation payments and, during such period of
continued payments, continues to be treated like an active Employee for purposes of participation in certain health and welfare
plans.

 

“Securities
Act” means the Securities Act of 1933, as amended, together with the rules and regulations promulgated thereunder.

 

“Security
Interest” means any mortgage, security interest, pledge, lien, charge, claim, option, right to acquire, voting or other
restriction, right-of-way, covenant, condition, easement, encroachment, restriction on transfer or other encumbrance of any nature
whatsoever.

 

    10

     

    

 

“Separation”
means (a) any actions to be taken pursuant to Article II and (b) any other transfers of Assets and assumptions of Liabilities,
in each case, between a member of one Group and a member of the other Group, provided for in this Agreement or in any Ancillary
Agreement.

 

“Shared Contract”
means any contract or agreement of any member of either Group that relates in any material respect to both the NBI Business and
the Neurotrope Business, including the contracts and agreements set forth on Schedule VI; provided that the Parties may, by mutual
consent, elect to include in, or exclude from, this definition any contract or agreement.

 

“Spin-Off”
means the Separation and the Distribution.

 

“Subsidiary”
of any Person means any corporation or other organization whether incorporated or unincorporated of which at least a majority of
the securities or interests having by the terms thereof ordinary voting power to elect at least a majority of the board of directors
or others performing similar functions with respect to such corporation or other organization, is directly or indirectly owned
or controlled by such Person or by any one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries.

 

“Tax Opinion
Representations” has the meaning set forth in the TMA.

 

“Taxes”
has the meaning set forth in the TMA.

 

“Third-Party
Claim” means any assertion by a Person (including any Governmental Authority) who is not a member of the Neurotrope Group
or NBI of any claim, or the commencement by any such Person of any Action, against any member of the Neurotrope Group or NBI.

 

“Third-Party
Proceeds” has the meaning set forth in Section 6.04(a).

 

“TMA”
means the Tax Matters Agreement dated as of the date of this Agreement by and between Neurotrope and NBI.

 

“U.S. Intended
Tax Treatment” has the meaning set forth in the TMA.

 

“Welfare Plan”
means each Benefit Plan that provides life insurance, health care, dental care, accidental death and dismemberment insurance, disability,
severance, vacation or other group welfare or fringe benefits.

 

“Workers’
Compensation Event” means the event, injury, illness or condition giving rise to a workers’ compensation claim
with respect to a NBI Employee.

 

“Workers’
Compensation Reimbursement Amounts” means the amount, if any, by which (i) the amount actually payable by the members
of the Neurotrope Group in respect of the participation of NBI Employees, Salary Continuation Former Employees and Former NBI Employees
in the Neurotrope Workers’ Compensation Plan for any period prior to the Workers’ Compensation Effective Date exceeds
(ii) the amount that the Neurotrope Group charged NBI in respect of such period of participation.

 

    11

     

    

 

 

ARTICLE
II

 

The Separation

 

SECTION
2.01                      Transfer
of Assets and Assumption of Liabilities. (a) Prior to the Distribution and subject to Section 2.01(e), the Parties shall cause
the Separation to be completed.

 

(b)           Subject
to Section 2.01(e), prior to the Distribution, the Parties shall, and shall cause their respective Group members to, execute such
instruments of assignment and transfer and take such other corporate actions as are necessary to (i) transfer and convey to NBI
all of the right, title and interest of the Neurotrope Group in, to and under all NBI Assets not already owned by NBI, (ii) transfer
and convey to one or more members of the Neurotrope Group all of the right, title and interest of NBI in, to and under all Neurotrope
Assets not already owned by the Neurotrope Group, (iii) cause NBI to assume all of the NBI Liabilities to the extent such Liabilities
would otherwise remain obligations of any member of the Neurotrope Group and (iv) cause one or more members of the Neurotrope
Group to assume all of the Neurotrope Liabilities to the extent such Liabilities would otherwise remain obligations of NBI. Notwithstanding
anything to the contrary, neither Party shall be required to transfer any Information except as required by Article VII.

 

(c)           In
the event that it is discovered after the Distribution that there was an omission of (i) the transfer or conveyance by NBI or
the acceptance or assumption by Neurotrope (or a member of the Neurotrope Group) of any Neurotrope Asset or Neurotrope Liability,
as the case may be, (ii) the transfer or conveyance by Neurotrope (or a member of the Neurotrope Group) or the acceptance or assumption
by NBI of any NBI Asset or NBI Liability, as the case may be, or (iii) the transfer or conveyance by one Party (or any other member
of its Group) to, or the acceptance or assumption by, the other Party (or any other member of its Group) of any Asset or Liability,
as the case may be, that, had the Parties given specific consideration to such Asset or Liability prior to the Distribution, would
have otherwise been so transferred, conveyed, accepted or assumed, as the case may be, pursuant to this Agreement or the Ancillary
Agreements, the Parties shall use reasonable best efforts to promptly effect such transfer, conveyance, acceptance or assumption
of such Asset or Liability. Any transfer, conveyance, acceptance or assumption made pursuant to this Section 2.01(c) shall be
treated by the Parties for all purposes as if it had occurred immediately prior to the Distribution, except as otherwise required
by applicable Law or a Determination.

 

(d)           In
the event that it is discovered after the Distribution that there was (i) a transfer or conveyance by NBI or the acceptance or
assumption by Neurotrope (or a member of the Neurotrope Group) of any NBI Asset or NBI Liability, as the case may be, or (ii)
a transfer or conveyance by Neurotrope (or a member of the Neurotrope Group) or the acceptance or assumption by NBI of any Neurotrope
Asset or Neurotrope Liability, as the case may be, the Parties shall use reasonable best efforts to promptly transfer or convey
such Asset back to the transferring or conveying Party or to rescind any acceptance or assumption of such Liability, as the case
may be. Any transfer or conveyance made or acceptance or assumption rescinded pursuant to this Section 2.01(d) shall be treated
by the Parties for all purposes as if such Asset or Liability had never been originally transferred, conveyed, accepted or assumed,
as the case may be, except as otherwise required by applicable Law or a Determination.

 

    12

     

    

 

(e)           To
the extent that any transfer or conveyance of any Asset or acceptance or assumption of any Liability required by this Agreement
to be so transferred, conveyed, accepted or assumed shall not have been completed prior to the Distribution, the Parties shall
use reasonable best efforts to effect such transfer, conveyance, acceptance or assumption as promptly following the Distribution
as shall be practicable. Nothing in this Agreement shall be deemed to require the transfer or conveyance of any Assets or the
acceptance or assumption of any Liabilities which by their terms or operation of law cannot be so transferred, conveyed, accepted
or assumed; provided, however, that the Parties shall use reasonable best efforts to obtain any necessary Consents for the transfer,
conveyance, acceptance or assumption (as applicable) of all Assets and Liabilities required by this Agreement to be so transferred,
conveyed, accepted or assumed. In the event that any such transfer, conveyance, acceptance or assumption (as applicable) has not
been completed effective as of and after the Distribution, the Party retaining such Asset or Liability shall thereafter hold such
Asset for the use and benefit of the Party entitled thereto (at the expense of the Party entitled thereto) and retain such Liability
for the account, and at the expense, of the Party by whom such Liability should have been assumed or accepted pursuant to this
Agreement, and take such other actions as may be reasonably requested by the Party to which such Asset should have been transferred
or conveyed, or by whom such Liability should have been assumed or accepted, as the case may be, in order to place such Party,
insofar as reasonably possible, in the same position as would have existed had such Asset or Liability been transferred, conveyed,
accepted or assumed (as applicable) as contemplated by this Agreement, including possession, use, risk of loss, potential for
gain and control over such Asset or Liability. As and when any such Asset or Liability becomes transferable, the Parties shall
use reasonable best efforts to promptly effect such transfer, conveyance, acceptance or assumption (as applicable). Any transfer,
conveyance, acceptance or assumption made pursuant to this Section 2.01(e) shall be treated by the Parties for all purposes as
if it had occurred immediately prior to the Distribution, except as otherwise required by applicable Law or a Determination.

 

(f)           The
Party retaining any Asset or Liability due to the deferral of the transfer and conveyance of such Asset or the deferral of the
acceptance and assumption of such Liability pursuant to this Section 2.01 or otherwise shall not be obligated by this Agreement,
in connection with this Section 2.01, to expend any money or take any action that would require the expenditure of money unless
and to the extent the Party entitled to such Asset or the Party intended to assume such Liability advances or agrees to reimburse
it for the necessary funds.

 

SECTION
2.02                      Certain
Matters Governed Exclusively by Ancillary Agreements. Each of Neurotrope and NBI agrees on behalf of itself and the members
of its Group that, except as explicitly provided in this Agreement or any Ancillary Agreement, the TMA shall exclusively govern
all matters relating to Taxes between such parties.

 

SECTION
2.03                      Termination
of Agreements. (a) Except as set forth in Section 2.03(b) or as otherwise provided by the steps constituting the Separation,
in furtherance of the releases and other provisions of Section 6.01, effective as of the Distribution, NBI, on the one hand, and
Neurotrope and each other member of the Neurotrope Group, on the other hand, hereby terminate any and all agreements, arrangements,
commitments and understandings, oral or written (“Intercompany Agreements”), including all intercompany accounts
payable or accounts receivable (“Intercompany Accounts”), between such parties and in effect or accrued as
of the Distribution. No such terminated Intercompany Agreement or Intercompany Account (including any provision thereof that purports
to survive termination) shall be of any further force or effect after the Distribution Date. Each Party shall, at the reasonable
request of the other Party, take, or cause to be taken, such other actions as may be necessary to effect the foregoing. The Parties,
on behalf of the members of their respective Groups, hereby waive any advance notice provision or other termination requirements
with respect to any Intercompany Agreement.

 

    13

     

    

 

(b)          The
provisions of Section 2.03(a) shall not apply to any of the following Intercompany Agreements or Intercompany Accounts (or to
any of the provisions thereof): (i) the Intercompany Agreements and Intercompany Accounts set forth in Schedule V; (ii) this Agreement
and the Ancillary Agreements (and each other Intercompany Agreement or Intercompany Account expressly contemplated by this Agreement
or any Ancillary Agreement to be entered into by either Party or any other member of its Group); (iii) any existing written Intercompany
Agreement to provide services between NBI, on the one hand, and a member of the Neurotrope Group, on the other hand, that has
been entered into in the ordinary course of business on an arm’s-length basis, including outstanding operational intercompany
trade receivables or payables incurred on such basis; (iv) any Intercompany Agreement to which any non-wholly owned Subsidiary
of NBI or Neurotrope, as the case may be, is a party; (v) any other Intercompany Agreements or Intercompany Accounts that this
Agreement or any Ancillary Agreement expressly contemplates will survive the Distribution Date; and (vi) any other Intercompany
Agreements or Intercompany Accounts that, had the Parties given specific consideration to such Intercompany Agreements or Intercompany
Accounts prior to the Distribution, would have been set forth in Schedule V as not to terminate as of the Distribution.

 

SECTION
2.04                     Shared
Contracts. The Parties shall, and shall cause the members of their respective Groups to, use their respective reasonable best
efforts to work together (and, if necessary and desirable, to work with the third party to such Shared Contract) in an effort
to divide, partially assign, modify and/or replicate (in whole or in part) the respective rights and obligations under and in
respect of any Shared Contract, such that (a) NBI is the beneficiary of the rights and is responsible for the obligations related
to that portion of such Shared Contract relating to the NBI Business (the “NBI Portion”), which rights shall
be a NBI Asset and which obligations shall be a NBI Liability and (b) a member of the Neurotrope Group is the beneficiary of the
rights and is responsible for the obligations related to such Shared Contract not relating to the NBI Business (the “Neurotrope
Portion”), which rights shall be a Neurotrope Asset and which obligations shall be a Neurotrope Liability. If the Parties,
or their respective Group members, as applicable, are not able to enter into an arrangement to formally divide, partially assign,
modify and/or replicate such Shared Contract prior to the Distribution as contemplated by the previous sentence, then the Parties
shall, and shall cause their respective Group members to, cooperate in any lawful arrangement to provide that, following the Distribution
and until the earlier of five years after the Distribution Date and such time as the formal division, partial assignment, modification
and/or replication of such Shared Contract as contemplated by the previous sentence is effected, NBI shall receive the interest
in the benefits and obligations of the NBI Portion under such Shared Contract and a member of the Neurotrope Group shall receive
the interest in the benefits and obligations of the Neurotrope Portion under such Shared Contract.

 

    14

     

    

 

SECTION
2.05                     Disclaimer
of Representations and Warranties. Each of Neurotrope (on behalf of itself and each other member of the Neurotrope Group)
and NBI understands and agrees that, except as expressly set forth in this Agreement, any Ancillary Agreement or the Tax Opinion
Representations, no party to this Agreement, any Ancillary Agreement or any other agreement or document contemplated by this Agreement
or any Ancillary Agreement is representing or warranting in any way as to any Assets or Liabilities transferred or assumed as
contemplated hereby or thereby, as to the sufficiency of the Assets or Liabilities transferred or assumed hereby or thereby for
the conduct and operations of the NBI Business or the Neurotrope Business, as applicable, as to any Governmental Approvals or
other Consents required in connection therewith or in connection with any past transfers of the Assets or assumptions of the Liabilities,
as to the value or freedom from any Security Interests of, or any other matter concerning, any Assets or Liabilities of such party,
or as to the absence of any defenses or rights of setoff or freedom from counterclaim with respect to any claim or other Asset,
including any accounts receivable, of any such Party, or as to the legal sufficiency of any assignment, document or instrument
delivered hereunder to convey title to any Asset or thing of value upon the execution, delivery and filing hereof or thereof.
Except as may expressly be set forth herein, any such Assets are being transferred on an “as is,” “where is”
basis and the respective transferees shall bear the economic and legal risks that (a) any conveyance shall prove to be insufficient
to vest in the transferee good and marketable title, free and clear of any Security Interest, and (b) any necessary Governmental
Approvals or other Consents are not obtained or that any requirements of Laws or judgments are not complied with.

 

SECTION
2.06                     Allocation
of Welfare Benefit Claims. (a) The members of the Neurotrope Group shall retain Liability and responsibility in accordance
with the applicable Neurotrope Welfare Plan for all reimbursement claims (such as medical and dental claims) for expenses incurred
and for all non-reimbursement claims (such as life insurance claims) incurred by NBI Employees and Salary Continuation Former
Employees (and their respective dependents and beneficiaries) under such plans prior to the Establishment Date of the corresponding
NBI Welfare Plan and (b) NBI shall retain Liability and responsibility in accordance with the NBI Welfare Plans for all reimbursement
claims (such as medical and dental claims) for expenses incurred and for all non-reimbursement claims (such as life insurance
claims) incurred by NBI Employees and Salary Continuation Former Employees (and their respective dependents and beneficiaries)
on or following such Establishment Date. For purposes of this Section 2.06, a benefit claim shall be deemed to be incurred as
follows: (A) when the event giving rise to the benefit under the applicable plan has occurred as set forth in the governing plan
documents, if it is clear based on the governing documents of both the Neurotrope Welfare Plan and NBI Welfare Plans which plan
should be responsible for the claim or if not, as follows: (B) (1) health, dental, vision, employee assistance program and prescription
drug benefits (including in respect of any hospital confinement), upon provision of such services, materials or supplies; and
(2) life, accidental death and dismemberment and business travel accident insurance benefits, upon the death, or other event giving
rise to such benefits. The members of the Neurotrope Group shall retain Liability and responsibility in accordance with the applicable
Neurotrope Welfare Plan for all reimbursement claims (such as medical and dental claims) for expenses incurred and for all non-reimbursement
claims (such as life insurance claims) for individuals who, immediately prior to the applicable Establishment Date, are Former
NBI Employees (and their dependents and beneficiaries), including any such Employee on long-term disability on the applicable
Establishment Date.

 

SECTION
2.07                     Workers’
Compensation Claims. In the case of any workers’ compensation claim of any NBI Employee who participates in a workers’
compensation program of a member of the Neurotrope Group (each, a “Neurotrope Workers’ Compensation Program”),
such claim shall be covered (a) under such Neurotrope Workers’ Compensation Program if the Workers’ Compensation Event
occurred prior to the Distribution Date (such date, as applicable, the “Workers’ Compensation Effective Date”),
and (b) under a workers’ compensation program of NBI (each, a “NBI Workers’ Compensation Program”)
if the Workers’ Compensation Event occurs on or after the Workers’ Compensation Effective Date. If the Workers’
Compensation Event occurs over a period both preceding and following the Workers’ Compensation Effective Date, the claim
shall be covered jointly under the Neurotrope Workers’ Compensation Program and the NBI Workers’ Compensation Program
and shall be equitably apportioned between them based upon the relative periods of time that the Workers’ Compensation Event
transpired preceding and following the Workers’ Compensation Effective Date. The members of the Neurotrope Group shall retain
Liability and responsibility in accordance with the Neurotrope Workers’ Compensation Program for all covered workers’
compensation claims incurred by individuals who, immediately prior to the Workers’ Compensation Effective Date, are Former
NBI Employees or Salary Continuation Former Employees, including any such Employee on long-term disability on the Workers’
Compensation Effective Date. Notwithstanding any provisions of this Section 2.07, NBI shall be obligated to reimburse Neurotrope
for the Worker’s Compensation Reimbursement Amounts in accordance with Section 2.08.

 

    15

     

    

 

SECTION
2.08                     Reimbursements
by NBI. Promptly following the end of each calendar quarter that ends following the Distribution, Neurotrope shall
provide NBI with one or more invoices that set forth the aggregate Workers’ Compensation Reimbursement Amounts incurred
by a member of the Neurotrope Group during such calendar quarter.
Within 20 days following NBI’s receipt of such invoice, NBI shall notify Neurotrope in
writing if NBI disagrees with any of the amounts set forth on such invoice and the reason for any such disagreement. If NBI does
not timely notify Neurotrope of any such disagreement, Neurotrope’s
determination as set forth on such invoice shall be conclusive, final
and binding. If NBI timely notifies Neurotrope of any such disagreement,
an officer of each Party shall meet during the 30-day period following NBI’s notification of disagreement and shall negotiate
in good faith to resolve the dispute during such period, and the resolution of such disagreement reached by such officers shall
be conclusive, final and binding. Within 60 days following the date such invoice becomes conclusive, final and binding, NBI shall
pay Neurotrope an amount in cash equal to the aggregate amounts
set forth on such invoice.

 

ARTICLE
III

 

Actions Pending the Distribution

 

SECTION
3.01                     Actions
Prior to the Distribution. (a) Subject to the conditions specified in Section 3.02 and subject to Section 4.03, Neurotrope
and NBI shall use reasonable best efforts to consummate the Distribution. Such efforts shall include taking the actions specified
in this Section 3.01.

 

(b)           Prior
to the Distribution, Neurotrope shall mail the Form S-1 to the Record Holders.

 

    16

     

    

 

(c)           NBI
shall prepare, file with the Commission and use its reasonable best efforts to cause to become effective any registration statements
or amendments thereto required to effect the establishment of, or amendments to, any employee benefit and other plans necessary
or appropriate in connection with the transactions contemplated by this Agreement or any of the Ancillary Agreements.

 

(d)           Neurotrope
and NBI shall take all such action as may be necessary or appropriate under the securities or blue sky laws of the states or other
political subdivisions of the United States or of other foreign jurisdictions in connection with the Distribution.

 

(e)           NBI
shall prepare and file, and shall use reasonable best efforts to have approved prior to the Distribution, an application for the
listing of the NBI Common Stock to be distributed in the Distribution on the over-the-counter market (the “OTC”),
or, if applicable, Nasdaq, subject to official notice of distribution.

 

(f)           Prior
to the Distribution, Neurotrope shall duly elect the individuals listed as members of the NBI board of directors in the Form S-1,
and such individuals shall be the members of the NBI board of directors effective as of immediately after the Distribution; provided,
however, that to the extent required by any Law or requirement of the OTC, or, if applicable, Nasdaq, or any other national securities
exchange, as applicable, one independent director shall be appointed by the existing board of directors of NBI and begin his or
her term prior to the Distribution and shall serve on NBI’s audit and finance committee, compensation committee and nominating
and corporate governance committee.

 

(g)          Prior
to the Distribution, Neurotrope shall deliver or cause to be delivered to NBI resignations, effective as of immediately after
the Distribution, of each individual who will be an employee of any member of the Neurotrope Group after the Distribution and
who is an officer or director of NBI immediately prior to the Distribution.

 

(h)              
Immediately prior to the Distribution, the Amended and Restated Certificate of Incorporation and the Amended and
Restated By-laws of NBI, each in substantially the form filed as an exhibit to the Form S-1, shall be in effect.

 

(i)            Prior
to the Distribution, NBI shall make capital and other expenditures and operate its cash management, accounts payable and receivables
collection systems in the ordinary course of business consistent with prior practice except as required in connection with the
transactions contemplated by this Agreement and Ancillary Agreements.

 

(j)            Neurotrope
and NBI shall, subject to Section 4.03, take all reasonable steps necessary and appropriate to cause the conditions set forth
in Section 3.02 to be satisfied and to effect the Distribution on the Distribution Date.

 

    17

     

    

 

SECTION
3.02                      Conditions
Precedent to Consummation of the Distribution. Subject to Section 4.03, following the consummation of the Merger and as soon
as practicable after the date of this Agreement, the Parties shall use reasonable best efforts to satisfy the following conditions
prior to the consummation of the Distribution. The obligations of the Parties to consummate the Distribution shall be conditioned
on the satisfaction, or waiver by Neurotrope, of the following conditions:

 

(a)           The
board of directors of Neurotrope shall have authorized and approved the Separation and Distribution and not withdrawn such authorization
and approval, and shall have declared the dividend of NBI Common Stock to Neurotrope shareholders.

 

(b)           Each
Ancillary Agreement shall have been executed by each party thereto.

 

(c)           The
Form S-1 shall have been declared effective by the Commission, no stop order suspending the effectiveness of the Form S-1 shall
be in effect and no proceedings for such purpose shall be pending before or threatened by the Commission.

 

(d)           The
NBI Common Stock shall have been accepted for listing on the OTC or, if applicable, Nasdaq or another national securities exchange
approved by Neurotrope, subject to official notice of distribution.

 

(e)           Neurotrope
shall have received the written opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., which shall remain in full force
and effect, that, subject to the accuracy of and compliance with the relevant Tax Opinion Representations, (i) the Distribution
should qualify for its U.S. Intended Tax Treatment and (ii) no “excess loss account” (within the meaning of Section
1.1502 of the Regulations) with respect to the NBI Common Stock should be taken into account as income or gain as a result of
any step of the Separation or the Distribution.

 

(f)            The
Separation shall have been completed.

 

(g)           No
order, injunction or decree issued by any Governmental Authority of competent jurisdiction or other legal restraint or prohibition
preventing the consummation of the Distribution shall be in effect, and no other event outside the control of Neurotrope shall
have occurred or failed to occur that prevents the consummation of the Distribution.

 

(h)           No
other events or developments shall have occurred prior to the Distribution that, in the judgment of the board of directors of
Neurotrope, would result in the Distribution having an adverse effect on Neurotrope or the shareholders of Neurotrope.

 

(i)            The
actions set forth in Sections 3.01(b), (f), (g) and (h) shall have been completed.

 

(j)            NBI
shall have delivered to Neurotrope a certificate signed by the Chief Financial Officer of NBI, dated as of the Distribution Date,
certifying that NBI has complied with Section 3.01(i).

 

The foregoing conditions
are for the sole benefit of Neurotrope and shall not give rise to or create any duty on the part of Neurotrope or the Neurotrope
board of directors to waive or not waive such conditions or in any way limit the right of Neurotrope to terminate this Agreement
as set forth in Article X or alter the consequences of any such termination from those specified in such Article. Any determination
made by the Neurotrope board of directors prior to the Distribution concerning the satisfaction or waiver of any or all of the
conditions set forth in this Section 3.02 shall be conclusive.

 

    18

     

    

 

ARTICLE
IV

 

The Distribution

 

SECTION
4.01                     The
Distribution. (a) NBI shall cooperate with Neurotrope to accomplish the Distribution and shall, at the direction of Neurotrope,
use its reasonable best efforts to promptly take any and all actions necessary or desirable to effect the Distribution. Neurotrope
shall select any investment bank or manager in connection with the Distribution, as well as any financial printer, distribution
agent and financial, legal, accounting and other advisors for Neurotrope. Neurotrope or NBI, as the case may be, will provide,
or cause the applicable member of its Group to provide, to the Agent all share certificates and any information required in order
to complete the Distribution.

 

(b)           Subject
to the terms and conditions set forth in this Agreement, (i) after completion of the Separation and on or prior to the Distribution
Date, for the benefit of and distribution to the holders of certain of Neurotrope’s equity securities (other than shares
of restricted stock issued pursuant to Neurotrope equity plans) as of the Record Date (“Record Holders”), Neurotrope
will deliver to the Agent all of the issued and outstanding shares of NBI Common Stock then owned by Neurotrope or any other member
of the Neurotrope Group and book-entry authorizations for such shares and (ii) on the Distribution Date, Neurotrope shall instruct
the Agent to distribute to each Record Holder (or such Record Holder’s bank or brokerage firm on such Record Holder’s
behalf) electronically, by direct registration in book-entry form, the number of shares of NBI Common Stock to which such Record
Holder is entitled based on a distribution ratio to be determined by Neurotrope in its sole discretion. The Distribution shall
be effective at 11:59 p.m. New York City time on the Distribution Date. On or as soon as practicable after the Distribution Date,
the Agent will mail to each Record Holder an account statement indicating the number of shares of NBI Common Stock that have been
registered in book-entry form in the name of such Record Holder.

 

SECTION
4.02                      Fractional
Shares. The Agent and Neurotrope shall, as soon as practicable after the Distribution Date, (a) determine the number of whole
shares and fractional shares of NBI Common Stock allocable to each Record Holder, (b) aggregate all such fractional shares into
whole shares and sell the whole shares obtained thereby in open market transactions at then prevailing trading prices on behalf
of holders who would otherwise be entitled to fractional share interests and (c) distribute to each such holder, or for the benefit
of each beneficial owner, such holder’s or owner’s ratable share of the net proceeds of such sale, based upon the
average gross selling price per share of NBI Common Stock after making appropriate deductions for any amount required to be withheld
under applicable Tax Law and less any brokers’ charges, commissions or transfer Taxes. The Agent, in its sole discretion,
will determine the timing and method of selling such fractional shares, the selling price of such fractional shares and the broker-dealer
through which such fractional shares will be sold; provided, however, that the designated broker-dealer is not an
Affiliate of Neurotrope or NBI. Neither Neurotrope nor NBI will pay any interest on the proceeds from the sale of fractional shares.

 

    19

     

    

 

SECTION
4.03                     Sole
Discretion of Neurotrope. Neurotrope shall, in its sole and absolute discretion, determine the Record Date, the Distribution
Date and all terms of the Distribution, including the form, structure and terms of any transactions and/or offerings to effect
the Distribution and the timing of and conditions to the consummation thereof. In addition and notwithstanding anything to the
contrary set forth below, Neurotrope may at any time and from time to time until the Distribution decide to abandon the Distribution
or modify or change the terms of the Distribution, including by accelerating or delaying the timing of the consummation of all
or part of the Distribution.

 

ARTICLE
V

 

Mutual Releases; Indemnification

 

SECTION
5.01                       Release
of Pre-Distribution Claims. (a) Except as provided in Section 5.01(c) or elsewhere in this Agreement or the Ancillary Agreements,
effective as of the Distribution, NBI does hereby, for itself, its respective Affiliates, to the extent it may legally do so,
successors and assigns, and all Persons who at any time on or prior to the Distribution have been shareholders, directors, officers,
agents or employees of NBI (in each case, in their respective capacities as such), remise, release and forever discharge Neurotrope
and the other members of the Neurotrope Group, their respective Affiliates, successors and assigns, and all Persons who at any
on or prior to the Distribution have been shareholders, directors, officers, agents or employees of any member of the Neurotrope
Group (in each case, in their respective capacities as such), and their respective heirs, executors, administrators, successors
and assigns, from any and all NBI Liabilities whatsoever, whether at law or in equity (including any right of contribution), whether
arising under any contract or agreement, by operation of law or otherwise, existing or arising from any acts or events occurring
or failing to occur or alleged to have occurred or to have failed to occur or any conditions existing or alleged to have existed
on or before the Distribution, including in connection with the Spin-Off and all other activities to implement the Spin-Off.

 

(b)           Except
as provided in Section 5.01(c) or elsewhere in this Agreement or the Ancillary Agreements, effective as of the Distribution, Neurotrope
does hereby, for itself and each other member of the Neurotrope Group, their respective Affiliates, to the extent it may legally
do so, successors and assigns, and all Persons who at any time on or prior to the Distribution have been shareholders, directors,
officers, agents or employees of any member of the Neurotrope Group (in each case, in their respective capacities as such), remise,
release and forever discharge NBI, its respective Affiliates, successors and assigns, and all Persons who at any time on or prior
to the Distribution have been shareholders, directors, officers, agents or employees of any member of NBI (in each case, in their
respective capacities as such), and their respective heirs, executors, administrators, successors and assigns, from any and all
Neurotrope Liabilities whatsoever, whether at law or in equity (including any right of contribution), whether arising under any
contract or agreement, by operation of law or otherwise, existing or arising from any acts or events occurring or failing to occur
or alleged to have occurred or to have failed to occur or any conditions existing or alleged to have existed on or before the
Distribution, including in connection with the Spin-Off and all other activities to implement the Spin-Off.

 

    20

     

    

 

(c)           Nothing
contained in Section 5.01(a) or (b) shall impair any right of any Person to enforce this Agreement, any Ancillary Agreement or
any Intercompany Agreement or Intercompany Account that is specified in Section 2.03(b) not to terminate as of the Distribution,
in each case in accordance with its terms. Nothing contained in Section 5.01(a) or (b) shall release any Person from:

 

(i)            any
Liability provided in or resulting from any agreement among any members of the Neurotrope Group or NBI that is specified in Section
2.03(b) as not to terminate as of the Distribution, or any other Liability specified in such Section 2.03(b) as not to terminate
as of the Distribution;

 

(ii)           any
Liability, contingent or otherwise, assumed, transferred, assigned or allocated to the Group of which such Person is a member
in accordance with, or any other Liability of any member of any Group under, this Agreement or any Ancillary Agreement;

 

(iii)          any
Liability provided in or resulting from any other agreement or understanding that is entered into after the Distribution between
one Party (and/or a member of such Party’s Group), on the one hand, and the other Party (and/or a member of such Party’s
Group), on the other hand;

 

(iv)          any
Liability that the Parties may have with respect to indemnification or contribution pursuant to this Agreement or any Ancillary
Agreement for claims brought against the Parties, the members of their respective Groups or any of their respective directors,
officers, employees or agents, by third Persons, which Liability shall be governed by the provisions of this Article V or, if
applicable, the appropriate provisions of the relevant Ancillary Agreement; or

 

(v)           any
Liability the release of which would result in the release of any Person not otherwise intended to be released pursuant to this
Section 5.01.

 

(d)          NBI
shall not make any claim or demand, or commence any Action asserting any claim or demand, including any claim of contribution
or any indemnification, against Neurotrope or any other member of the Neurotrope Group, or any other Person released pursuant
to Section 5.01(a), with respect to any Liabilities released pursuant to Section 5.01(a). Neurotrope shall not make, and shall
not permit any other member of the Neurotrope Group to make, any claim or demand, or commence any Action asserting any claim or
demand, including any claim of contribution or any indemnification against NBI, or any other Person released pursuant to Section
5.01(b), with respect to any Liabilities released pursuant to Section 5.01(b).

 

(e)           It
is the intent of each of Neurotrope and NBI, by virtue of the provisions of this Section 5.01, to provide for a full and complete
release and discharge of all Liabilities existing or arising from all acts and events occurring or failing to occur or alleged
to have occurred or to have failed to occur and all conditions existing or alleged to have existed on or before the Distribution
Date, between or among NBI, on the one hand, and Neurotrope or any other member of the Neurotrope Group, on the other hand (including
any contractual agreements or arrangements existing or alleged to exist between or among any such members on or before the Distribution
Date), except as set forth in Section 5.01(c) or elsewhere in this Agreement or in any Ancillary Agreement. At any time, at the
request of the other Party, each Party shall cause each member of its respective Group to execute and deliver releases reflecting
the provisions hereof.

 

    21

     

    

 

SECTION
5.02                     Indemnification
by NBI. Subject to Section 5.04, NBI shall indemnify, defend and hold harmless Neurotrope each other member of the Neurotrope
Group and each of their respective former and current directors, officers and employees, and each of the heirs, executors, successors
and assigns of any of the foregoing (collectively, the “Neurotrope Indemnitees”), from and against any and
all Liabilities of the Neurotrope Indemnitees relating to, arising out of or resulting from any of the following items (without
duplication):

 

(a)           the
NBI Liabilities, including the failure of NBI or any other Person to pay, perform or otherwise promptly discharge any NBI Liability
in accordance with its terms;

 

(b)           any
breach by NBI of this Agreement or any Ancillary Agreement unless such Ancillary Agreement expressly provides for separate indemnification
therein (which shall be controlling); and

 

(c)           any
breach by NBI of any of the representations and warranties made by NBI in Section 11.01(c).

 

SECTION
5.03                      Indemnification
by Neurotrope. Subject to Section 5.04, Neurotrope shall indemnify, defend and hold harmless NBI and each of its respective
former and current directors, officers and employees, and each of the heirs, executors, successors and assigns of any of the foregoing
(collectively, the “NBI Indemnitees”), from and against any and all Liabilities of the NBI Indemnitees relating
to, arising out of or resulting from any of the following items (without duplication):

 

(a)            the
Neurotrope Liabilities, including the failure of Neurotrope or any other member of the Neurotrope Group or any other Person to
pay, perform or otherwise promptly discharge any Neurotrope Liability in accordance with its terms;

 

(b)           any
breach by Neurotrope or any other member of the Neurotrope Group of this Agreement or any Ancillary Agreement unless such Ancillary
Agreement expressly provides for separate indemnification therein (which shall be controlling); and

 

(c)           any
breach by Neurotrope of any of the representations and warranties made by Neurotrope on behalf of itself and the members of the
Neurotrope Group in Section 11.01(c).

 

SECTION
5.04                       Indemnification
Obligations Net of Insurance Proceeds and Third-Party Proceeds.

 

(a)           The
Parties intend that any Liability subject to indemnification or reimbursement pursuant to this Agreement will be net of (i) Insurance
Proceeds that actually reduce the amount of, or are paid to the applicable Indemnitee in respect of, such Liability or (ii) other
amounts recovered from any third party that actually reduce the amount of, or are paid to the applicable Indemnitee in respect
of, such Liability (“Third-Party Proceeds”). Accordingly, the amount that either Party (an “Indemnifying
Party”) is required to pay to any Person entitled to indemnification or reimbursement pursuant to this Agreement (an
 “Indemnitee”) will be reduced by any Insurance Proceeds or Third-Party Proceeds theretofore actually recovered
by or on behalf of the Indemnitee from a third party in respect of the related Liability. If an Indemnitee receives a payment required
by this Agreement from an Indemnifying Party in respect of any Liability (an “Indemnity Payment”) and subsequently
receives Insurance Proceeds or Third-Party Proceeds in respect of such Liability, then the Indemnitee will pay to the Indemnifying
Party an amount equal to the excess of the Indemnity Payment received over the amount of the Indemnity Payment that would have
been due if such Insurance Proceeds or Third-Party Proceeds had been received, realized or recovered before the Indemnity Payment
was made.

 

    22

     

    

 

(b)           An
insurer that would otherwise be obligated to pay any claim shall not be relieved of the responsibility with respect thereto or
have any subrogation rights with respect thereto by virtue of the indemnification provisions hereof, it being expressly understood
and agreed that no insurer or any other third party shall be entitled to a “wind-fall” (i.e., a benefit they
would not be entitled to receive in the absence of the indemnification provisions) by virtue of the indemnification provisions
hereof. Each member of the Neurotrope Group and NBI shall use reasonable best efforts to seek to collect or recover any Insurance
Proceeds and any Third-Party Proceeds to which such Person is entitled in connection with any Liability for which such Person
seeks indemnification pursuant to this Article V; provided, however, that such Person’s inability to collect
or recover any such Insurance Proceeds or Third-Party Proceeds shall not limit the Indemnifying Party’s obligations hereunder.

 

(c)           The
calculation of any Indemnity Payments required by this Agreement shall be subject to Section 5.04 of the TMA.

 

SECTION
5.05                     Procedures
for Indemnification of Third-Party Claims. (a) If an Indemnitee shall receive notice or otherwise learn of a Third-Party Claim
with respect to which an Indemnifying Party may be obligated to provide indemnification to such Indemnitee pursuant to this Agreement,
such Indemnitee shall give such Indemnifying Party written notice thereof as soon as reasonably practicable, but no later than
30 days after becoming aware of such Third-Party Claim. Any such notice shall describe the Third-Party Claim in reasonable detail.
Notwithstanding the foregoing, the failure of any Indemnitee or other Person to give notice as provided in this Section 5.05(a)
shall not relieve the related Indemnifying Party of its obligations under this Article VI, except to the extent that such Indemnifying
Party is actually prejudiced by such failure to give notice.

 

(b)           The
Indemnifying Party shall have the right, exercisable by written notice to the Indemnitee within 30 calendar days after receipt
of notice from an Indemnitee in accordance with Section 5.05(a) (or sooner, if the nature of such Third-Party Claim so requires),
to assume and conduct the defense of such Third-Party Claim in accordance with the limits set forth in this Agreement with counsel
selected by the Indemnifying Party and reasonably acceptable to the Indemnitee; provided, however, that (i) the
defense of such Third-Party Claim by the Indemnifying Party will not, in the reasonable judgment of the Indemnitee, affect the
Indemnitee or any of its controlled Affiliates in a materially adverse manner and (ii) the Third-Party Claim solely seeks (and
continues to seek) monetary damages (the conditions set forth in clauses (i) and (ii), collectively, the “Litigation
Conditions”).

 

(c)            If
the Indemnifying Party elects not to assume the defense of a Third-Party Claim in accordance with this Agreement, or fails to
notify an Indemnitee of its election as provided in Section 5.05(b), such Indemnitee may defend such Third-Party Claim at the
cost and expense of the Indemnifying Party.

 

    23

     

    

 

(d)           If
the Indemnifying Party elects to assume the defense of a Third-Party Claim in accordance with the terms of this Agreement, the
Indemnitees shall, subject to the terms of this Agreement, cooperate with the Indemnifying Party with respect to the defense of
such Third-Party Claim.

 

(e)            If
the Indemnifying Party elects to assume the defense of a Third-Party Claim in accordance with the terms of this Agreement, the
Indemnifying Party will not be liable for any additional legal expenses subsequently incurred by the Indemnitee in connection
with the defense of the Third-Party Claim; provided, however, that if (i) the Litigation Conditions cease to be
met or (ii) the Indemnifying Party fails to take reasonable steps necessary to defend diligently such Third-Party Claim, the Indemnitee
may assume its own defense, and the Indemnifying Party will be liable for all reasonable costs or expenses paid or incurred in
connection with such defense. The Indemnifying Party or the Indemnitee, as the case may be, shall have the right to participate
in (but, subject to the prior sentence, not control), at its own expense, the defense of any Third-Party Claim that the other
is defending as provided in this Agreement. In the event, however, that such Indemnitee reasonably determines that representation
by counsel to the Indemnifying Party of both such Indemnifying Party and the Indemnitee could reasonably be expected to present
such counsel with a conflict of interest, then the Indemnitee may employ separate counsel to represent or defend it in any such
action or proceeding and the Indemnifying Party will pay the reasonable fees and expenses of such counsel.

 

(f)            No
Indemnifying Party shall consent to entry of any judgment or enter into any settlement of any Third-Party Claim without the consent
of the applicable Indemnitee or Indemnitees; provided, however, that such Indemnitee(s) shall be required to consent
to such entry of judgment or to such settlement that the Indemnifying Party may recommend if the judgment or settlement (i) contains
no finding or admission of any violation of Law or any violation of the rights of any Person, (ii) involves only monetary relief
which the Indemnifying Party has agreed to pay and (iii) includes a full and unconditional release of the Indemnitee. Notwithstanding
the foregoing, in no event shall an Indemnitee be required to consent to any entry of judgment or settlement if the effect thereof
is to permit any injunction, declaratory judgment, other order or other nonmonetary relief to be entered, directly or indirectly,
against any Indemnitee.

 

(g)           Whether
or not the Indemnifying Party assumes the defense of a Third-Party Claim, no Indemnitee shall admit any liability with respect
to, or settle, compromise or discharge, such Third-Party Claim without the Indemnifying Party’s prior written consent (such
consent not to be unreasonably withheld or delayed).

 

SECTION
5.06                      Additional
Matters. (a) Any claim on account of a Liability that does not result from a Third-Party Claim shall be asserted by written
notice given by the Indemnitee to the related Indemnifying Party. Such Indemnifying Party shall have a period of 30 days after
the receipt of such notice within which to respond thereto. If such Indemnifying Party does not respond within such 30-day period,
such Indemnifying Party shall be deemed to have refused to accept responsibility to make payment. If such Indemnifying Party does
not respond within such 30-day period or rejects such claim in whole or in part, such Indemnitee shall be free to pursue such
remedies as may be available to such Party as contemplated by this Agreement.

 

    24

     

    

 

 

(b)               In the event of payment by or on behalf of any Indemnifying Party to any Indemnitee in connection with any Third-Party
Claim, such Indemnifying Party shall be subrogated to and shall stand in the place of such Indemnitee as to any events or circumstances
in respect of which such Indemnitee may have any right, defense or claim relating to such Third-Party Claim against any claimant
or plaintiff asserting such Third-Party Claim or against any other Person. Such Indemnitee shall cooperate with such Indemnifying
Party in a reasonable manner, and at the cost and expense of such Indemnifying Party, in prosecuting any subrogated right, defense
or claim.

 

(c)               In the event of an Action relating to a Liability that has been allocated to an Indemnifying Party pursuant to the
terms of this Agreement or any Ancillary Agreement in which the Indemnifying Party is not a named defendant, if the Indemnifying
Party shall so request, the Parties shall endeavor to substitute the Indemnifying Party for the named defendant or add the Indemnifying
Party as an additional named defendant, if at all practicable. If such substitution or addition cannot be achieved for any reason
or is not requested, the named defendant shall allow the Indemnifying Party to manage the Action as set forth in this Section 6.06,
the Indemnifying Party shall fully indemnify the named defendant against all reasonable costs of defending the Action (including
court costs, sanctions imposed by a court, attorneys’ fees, experts, fees and all other external expenses), the costs of
any judgment or settlement and the cost of any interest or penalties relating to any judgment or settlement.

 

SECTION
5.07                      Remedies Cumulative. The remedies provided in this Article V shall be cumulative and, subject to the provisions
of Article IX, shall not preclude assertion by any Indemnitee of any other rights or the seeking of any and all other remedies
against any Indemnifying Party.

 

SECTION
5.08                      Survival of Indemnities. The rights and obligations of each of Neurotrope and NBI and their respective Indemnitees
under this Article VI shall survive the sale or other transfer by any Party or its Affiliates of any Assets or businesses or the
assignment by it of any Liabilities.

 

SECTION
5.09                      Limitation on Liability. Except as may expressly be set forth in this Agreement, none of Neurotrope, NBI or
any other member of either Group shall in any event have any Liability to the other or to any other member of the other’s
Group, or to any other Neurotrope Indemnitee or NBI Indemnitee, as applicable, under this Agreement (i) with respect to any matter
to the extent that such Party seeking indemnification has engaged in any knowing violation of Law or fraud in connection therewith
or (ii) for any indirect, special, punitive or consequential damages, whether or not caused by or resulting from negligence or
breach of obligations hereunder and whether or not informed of the possibility of the existence of such damages; provided, however,
that the provisions of this Section 5.09(ii) shall not limit an Indemnifying Party’s indemnification obligations hereunder
with respect to any Liability any Indemnitee may have to any third party not affiliated with any member of the Neurotrope Group
or NBI for any indirect, special, punitive or consequential damages.

 

    25

     

    

 

ARTICLE
VI

 

Access to Information; Confidentiality

 

SECTION
6.01                      Agreement for Exchange of Information; Archives. (a) Except in the case of an adversarial Action or threatened
adversarial Action by either Neurotrope or NBI or a Person or Persons in its Group against the other Party or a Person or Persons
in its Group, and subject to Section 6.01(b), each of Neurotrope and NBI, on behalf of its respective Group, shall provide, or
cause to be provided, to the other Party, at any time after the Distribution, as soon as reasonably practicable after written request
therefor, any Information relating to time periods on or prior to the Distribution Date in the possession or under the control
of such respective Group, which Neurotrope or NBI, or any member of its respective Group, as applicable, reasonably needs (i) to
comply with reporting, disclosure, filing or other requirements imposed on Neurotrope or NBI, or any member of its respective Group,
as applicable (including under applicable securities Laws), by any national securities exchange or any Governmental Authority having
jurisdiction over Neurotrope or NBI, or any member of its respective Group, as applicable, (ii) for use in any other judicial,
regulatory, administrative or other proceeding or in order to satisfy audit, accounting, regulatory, litigation or other similar
requirements or (iii) to comply with its obligations under this Agreement or any Ancillary Agreement. The receiving Party shall
use any Information received pursuant to this Section 6.01(a) solely to the extent reasonably necessary to satisfy the applicable
obligations or requirements described in clause (i), (ii) or (iii) of the immediately preceding sentence.

 

(b)               In the event that either Neurotrope or NBI determines that the exchange of any Information pursuant to Section 6.01(a)
could be commercially detrimental, violate any Law or agreement or waive or jeopardize any attorney-client privilege or attorney
work product protection, such Party shall not be required to provide access to or furnish such Information to the other Party;
provided, however, that both Neurotrope and NBI shall take all commercially reasonable measures to permit the compliance
with Section 6.01(a) in a manner that avoids any such harm or consequence. Both Neurotrope and NBI intend that any provision of
access to or the furnishing of Information pursuant to this Section 7.01 that would otherwise be within the ambit of any legal
privilege shall not operate as waiver of such privilege.

 

(c)               Each of NBI and Neurotrope agrees, on behalf of itself and each member of the Group of which it is a member, not
to disclose or otherwise waive any privilege or protection attaching to any privileged Information relating to a member of the
other Group or relating to or arising in connection with the relationship between the Groups prior to the Distribution, without
providing prompt written notice to and obtaining the prior written consent of the other (not to be unreasonably withheld or delayed).

 

(d)               Neurotrope and NBI each agree that it will only process personal data provided to it by the other Group in accordance
with all applicable privacy and data protection Law obligations and will implement and maintain at all times appropriate technical
and organizational measures to protect such personal data against unauthorized or unlawful processing and accidental loss, destruction,
damage, alteration and disclosure. In addition, each Party agrees to provide reasonable assistance to the other Party in respect
of any obligations under privacy and data protection legislation affecting the disclosure of such personal data to the other Party
and will not knowingly process such personal data in such a way to cause the other Party to violate any of its obligations under
any applicable privacy and data protection legislation.

 

    26

     

    

 

SECTION
6.02                      Ownership of Information. Any Information owned by one Group that is provided to the requesting Party hereunder
shall be deemed to remain the property of the providing Party. Except as specifically set forth herein, nothing herein shall be
construed as granting or conferring rights of license or otherwise in any such Information.

 

SECTION
6.03                      Compensation for Providing Information. Neurotrope and NBI shall reimburse each other for the reasonable costs,
if any, in complying with a request for Information pursuant to this Article VI. Except as may be otherwise specifically provided
elsewhere in this Agreement, such costs shall be computed in accordance with NBI’s or Neurotrope’s, as applicable,
standard methodology and procedures.

 

SECTION
6.04                       Record Retention. To facilitate the possible exchange of Information pursuant to this Article VI and other
provisions of this Agreement, each Party shall use its reasonable best efforts to retain all Information in such Party’s
possession relating to the other Party or its businesses, Assets or Liabilities, this Agreement or the Ancillary Agreements (the
 “Retained Information”) in accordance with its respective record retention policy as in effect on the date hereof or
such longer or shorter period as required by Law, this Agreement or the Ancillary Agreements.

 

SECTION
6.05                       Accounting Information. Without limiting the generality of Section 6.01 but subject to Section 6.01(b):

 

(a)               Until the end of the first full fiscal year occurring after the Distribution Date (and for a reasonable period of
time afterwards as required by Law for Neurotrope to prepare consolidated financial statements or complete a financial statement
audit for any period during which the financial results of NBI were consolidated with those of Neurotrope ), NBI shall use its
reasonable best efforts to enable Neurotrope to meet its timetable for dissemination of its financial statements and to enable
Neurotrope’s auditors to timely complete their annual audit and quarterly reviews of financial statements. As part of such
efforts, to the extent reasonably necessary for the preparation of financial statements or completing an audit or review of financial
statements or an audit of internal control over financial reporting, (i) NBI shall authorize and direct its auditors to make available
to Neurotrope’s auditors, within a reasonable time prior to the date of Neurotrope’s auditors’ opinion or review
report, both (x) the personnel who performed or will perform the annual audits and quarterly reviews of NBI and (y) work papers
related to such annual audits and quarterly reviews, to enable Neurotrope’s auditors to perform any procedures they consider
reasonably necessary to take responsibility for the work of NBI’s auditors as it relates to Neurotrope’s auditors’
opinion or report and (ii) until all governmental audits are complete, NBI shall provide reasonable access during normal business
hours for Neurotrope’s internal auditors, counsel and other designated representatives to (x) the premises of NBI and its
Subsidiaries and all Information (and duplicating rights) within the knowledge, possession or control of NBI and its Subsidiaries
and (y) the officers and employees of NBI and its Subsidiaries, so that Neurotrope may conduct reasonable audits relating to the
financial statements provided by NBI and its Subsidiaries; provided, however, that such access shall not be unreasonably
disruptive to the business and affairs of NBI.

 

    27

     

    

 

(b)               Until the end of the first full fiscal year occurring after the Distribution Date (and for a reasonable period of
time afterwards or as required by Law), Neurotrope shall use its reasonable best efforts to enable NBI to meet its timetable for
dissemination of its financial statements and to enable NBI’s auditors to timely complete their annual audit and quarterly
reviews of financial statements. As part of such efforts, to the extent reasonably necessary for the preparation of financial statements
or completing an audit or review of financial statements or an audit of internal control over financial reporting, (i) Neurotrope
shall authorize and direct its auditors to make available to NBI’s auditors, within a reasonable time prior to the date of
NBI’s auditors’ opinion or review report, both (x) the personnel who performed or will perform the annual audits and
quarterly reviews of Neurotrope and (y) work papers related to such annual audits and quarterly reviews, to enable NBI’s
auditors to perform any procedures they consider reasonably necessary to take responsibility for the work of Neurotrope’s
auditors as it relates to NBI’s auditors’ opinion or report and (ii) until all governmental audits are complete, Neurotrope
shall provide reasonable access during normal business hours for NBI’s internal auditors, counsel and other designated representatives
to (x) the premises of Neurotrope and its Subsidiaries and all Information (and duplicating rights) within the knowledge, possession
or control of Neurotrope and its Subsidiaries and (y) the officers and employees of Neurotrope and its Subsidiaries, so that NBI
may conduct reasonable audits relating to the financial statements provided by Neurotrope and its Subsidiaries; provided,
however, that such access shall not be unreasonably disruptive to the business and affairs of the Neurotrope Group.

 

(c)               In order to enable the principal executive officer(s) and principal financial officer(s) (as such terms are defined
in the rules and regulations of the Commission) of Neurotrope to make any certifications required of them under Section 302 or
906 of the Sarbanes-Oxley Act of 2002, NBI shall, within a reasonable period of time following a request from Neurotrope in anticipation
of filing such reports, cause its principal executive officer(s) and principal financial officer(s) to provide Neurotrope with
certifications of such officers in support of the certifications of Neurotrope’s principal executive officer(s) and principal
financial officer(s) required under Section 302 or 906 of the Sarbanes-Oxley Act of 2002 with respect to Neurotrope’s Quarterly
Report on Form 10-Q filed with respect to the fiscal quarter during which the Distribution Date occurs (unless such quarter is
the fourth fiscal quarter), each subsequent fiscal quarter through the third fiscal quarter of the year in which the Distribution
Date occurs and Neurotrope’s Annual Report on Form 10-K filed with respect to the fiscal year during which the Distribution
Date occurs. Such certifications shall be provided in substantially the same form and manner as such NBI officers provided prior
to the Distribution (reflecting any changes in certifications necessitated by the Spin- Off or any other transactions related thereto)
or as otherwise agreed upon between Neurotrope and NBI.

 

SECTION
6.06                      Limitations of Liability. Neither Neurotrope nor NBI shall have any Liability to the other Party in the event
that any Information exchanged or provided pursuant to this Agreement that is an estimate or forecast, or that is based on an estimate
or forecast, is found to be inaccurate in the absence of willful misconduct by the providing Person. Neither Neurotrope nor NBI
shall have any Liability to the other Party if any Information is destroyed after reasonable best efforts by NBI or Neurotrope,
as applicable, to comply with the provisions of Section 6.04.

 

    28

     

    

 

SECTION
6.07                      Production of Witnesses; Records; Cooperation. (a) After the Distribution Date and until the third anniversary
thereof, except in the case of an adversarial Action or threatened adversarial Action by either Neurotrope or NBI or a Person or
Persons in its Group against the other Party or a Person or Persons in its Group, each of Neurotrope and NBI shall take all reasonable
steps to make available, upon written request, the former, current and future directors, officers, employees, other personnel and
agents of the Persons in its respective Group (whether as witnesses or otherwise) and any books, records or other documents within
its control or that it otherwise has the ability to make available, to the extent that such Person (giving consideration to business
demands of such directors, officers, employees, other personnel and agents) or books, records or other documents may reasonably
be required in connection with any Action or threatened or contemplated Action (including preparation for such Action) in which
Neurotrope or NBI, as applicable, may from time to time be involved, regardless of whether such Action is a matter with respect
to which indemnification may be sought hereunder. The requesting Party shall bear all reasonable out-of-pocket costs and expenses
in connection therewith.

 

(b)               Without limiting the foregoing, Neurotrope and NBI shall use their reasonable best efforts to cooperate and consult
to the extent reasonably necessary with respect to any Actions or threatened or contemplated Actions, other than an adversarial
Action against the other Group.

 

(c)               The obligation of Neurotrope and NBI to make available former, current and future directors, officers, employees
and other personnel and agents or provide witnesses and experts pursuant to this Section 6.07 is intended to be interpreted in
a manner so as to facilitate cooperation and shall include the obligation to make available employees and other officers without
regard to whether such individual or the employer of such individual could assert a possible business conflict (subject to the
exception set forth in the first sentence of Section 6.07(a)). Without limiting the foregoing, each of Neurotrope and NBI agrees
that neither it nor any Person or Persons in its respective Group will take any adverse action against any employee of its Group
based on such employee’s provision of assistance or information to each other pursuant to this Section 6.07.

 

(d)               Upon the reasonable request of Neurotrope or NBI, in connection with any Action contemplated by this Article VII,
Neurotrope and NBI will enter into a mutually acceptable common interest agreement so as to maintain to the extent practicable
any applicable attorney-client privilege or work product immunity of any member of either Group.

 

SECTION
6.08                      Confidential Information. (a) Each of Neurotrope and NBI, on behalf of itself and each Person in its respective
Group, shall hold, and cause its respective directors, officers, employees, agents, accountants, counsel and other advisors and
representatives to hold, in strict confidence and not release or disclose, with at least the same degree of care, but no less than
a reasonable degree of care, that it applies to its own confidential and proprietary information pursuant to policies in effect
as of the Distribution Date, all Information concerning the other Group or its business that is either in its possession (including
Information in its possession prior to the Distribution) or furnished by the other Group or its respective directors, officers,
employees, agents, accountants, counsel and other advisors and representatives at any time pursuant to this Agreement, and shall
not use any such Information other than for such purposes as shall be expressly permitted hereunder, except, in each case, to the
extent that such Information is (i) in the public domain through no fault of any member of the Neurotrope Group or NBI, as applicable,
or any of its respective directors, officers, employees, agents, accountants, counsel and other advisors and representatives, (ii)
later lawfully acquired from other sources by any of Neurotrope, NBI or its respective Group, employees, directors or agents, accountants,
counsel and other advisors and representatives, as applicable, which sources are not themselves bound by a confidentiality obligation
to the knowledge of any of Neurotrope, NBI or Persons in its respective Group, as applicable, (iii) independently generated without
reference to any proprietary or confidential Information of the Neurotrope Group or NBI, as applicable, or (iv) required to be
disclosed by Law; provided, however, that the Person required to disclose such Information gives the applicable Person
prompt, and to the extent reasonably practicable, prior notice of such disclosure and an opportunity to contest such disclosure
and shall use commercially reasonable efforts to cooperate, at the expense of the requesting Person, in seeking any reasonable
protective arrangements requested by such Person. In the event that such appropriate protective order or other remedy is not obtained,
the Person that is required to disclose such Information shall furnish, or cause to be furnished, only that portion of such Information
that is legally required to be disclosed and shall take commercially reasonable steps to ensure that confidential treatment is
accorded such Information.

 

    29

     

    

 

Notwithstanding the
foregoing, each of Neurotrope and NBI may release or disclose, or permit to be released or disclosed, any such Information concerning
the other Group (x) to their respective directors, officers, employees, agents, accountants, counsel and other advisors and representatives
who need to know such Information (who shall be advised of the obligations hereunder with respect to such Information), and (y)
to any nationally recognized statistical rating organization as it reasonably deems necessary, solely for the purpose of obtaining
a rating of securities or other debt instruments upon normal terms and conditions; provided, however, that the Party whose Information
is being disclosed or released to such rating organization is promptly notified thereof.

 

(b)               Without limiting the foregoing, when any Information concerning the other Group or its business is no longer needed
for the purposes contemplated by this Agreement or any Ancillary Agreement, each of Neurotrope and NBI will, promptly after request
of the other Party, either return all Information in a tangible form (including all copies thereof and all notes, extracts or summaries
based thereon) or certify to the other Party, as applicable, that it has destroyed such Information (and used commercially reasonable
efforts to destroy all such Information electronically preserved or recorded within any computerized data storage device or component
(including any hard-drive or database)).

 

ARTICLE
VII

 

Insurance

 

SECTION
7.01                      Insurance. (a) Until and including the Distribution Date, Neurotrope shall (i) cause NBI and its respective
employees, officers and directors to continue to be covered as insured parties under Neurotrope’s policies of insurance in
a manner which is no less favorable than the coverage provided for the Neurotrope Group and (ii) permit NBI and its respective
employees, officers and directors to submit claims arising from or relating to facts, circumstances, events or matters that occurred
on or prior to the Distribution Date to the extent permitted under such policies. With respect to policies currently procured by
NBI for its sole benefit, NBI shall continue to maintain such insurance coverage through the Distribution Date in a manner no less
favorable than currently provided. Without limiting any of the rights or obligations of the parties pursuant to Section 7.01(b),
Neurotrope and NBI acknowledge that, as of immediately after the Distribution Date, and upon confirmation that NBI has secured
replacement coverage, Neurotrope intends to take such action as it may deem necessary or desirable to NBI and its respective employees,
officers and directors as insured parties under any policy of insurance issued to any member of the Neurotrope Group by any insurance
carrier effective immediately following the Distribution Date.

 

    30

     

    

 

NBI will not be entitled
following the Distribution Date, absent mutual agreement otherwise, to make any claims for insurance thereunder to the extent such
claims are based upon facts, circumstances, events or matters occurring after the Distribution Date or to the extent any claims
are made pursuant to any Neurotrope claims-made policies after the Distribution Date. No member of the Neurotrope Group shall be
deemed to have made any representation or warranty as to the availability of any coverage under any such insurance policy. Notwithstanding
the foregoing, Neurotrope shall, and shall cause the other members of the Neurotrope Group to, use reasonable best efforts to take
such actions as are necessary to cause all insurance policies of the Neurotrope Group that immediately prior to the Distribution
provide coverage to or with respect to NBI and its respective employees, officers and directors to continue to provide such coverage
with respect to acts, omissions or events occurring prior to the Distribution or claims made prior to the Distribution in accordance
with their terms as if the Distribution had not occurred and Neurotrope shall provide, and shall cause other members of the Neurotrope
Group to provide, such cooperation as is reasonably requested by NBI in order for NBI to have in effect after the Distribution
Date such new claims-made policies as NBI deems appropriate with respect to claims made after the Distribution Date. In no event
shall Neurotrope be required, at its own expense or with any detriment to Neurotrope, to extend or maintain coverage under claims-made
policies with respect to any claims first made against NBI or first reported to the insurer after the Distribution Date.

 

(b)               After the Distribution Date, NBI shall have the right to participate with Neurotrope to resolve Pre- Separation Insurance
Claims under the applicable Neurotrope insurance policies up to the full extent of the applicable and available limits of Liability
of such policy. Neurotrope or NBI, as the case may be, shall have primary control over those Pre-Separation Insurance Claims for
which the Neurotrope Group or NBI, respectively, bears the underlying loss, subject to the terms and conditions of the relevant
policy of insurance governing such control. If NBI is unable to assert a Pre-Separation Insurance Claim because it is no longer
an “insured” under a Neurotrope insurance policy, then Neurotrope shall assert such claim in its own name and deliver
the Insurance Proceeds to NBI. Any Insurance Proceeds received by the Neurotrope Group for NBI shall be for the benefit of NBI.
Any Insurance Proceeds received for the benefit of both the Neurotrope Group and NBI shall be distributed pro rata based on the
respective share of the underlying loss.

 

(c)               With respect to Pre-Separation Insurance Claims, whether or not known or reported on or prior to the Distribution
Date, NBI shall report as soon as practicable such claims arising from the NBI Business directly to the applicable insurer(s) and
to Neurotrope, and NBI shall, individually, and not jointly, assume and be responsible for the reimbursement Liability (i.e., deductible
or retention) related to its portion of the Liability and/or any retrospective premium charges associated with the workers compensation,
automobile and general liability claims so submitted by it to the extent such amounts payable by Neurotrope after the Distribution
Date are greater than they otherwise would have been if such amounts had been based on the most recent actuarial projections established
for such claims immediately prior to the Distribution, unless otherwise agreed in writing by Neurotrope. Neurotrope shall, and
shall cause each member of the Neurotrope Group to, cooperate and assist NBI with respect to such claims and shall arrange for
NBI to post any such collateral in respect of the reimbursement obligations as may reasonably be requested by the insurers. In
addition, Neurotrope shall provide information to NBI on claims history including quarterly loss reports and annual actuarial claims
reports for the previous five policy terms. Neurotrope agrees that Pre-Separation Insurance Claims of NBI shall receive the same
priority as Pre-Separation Insurance Claims of members of the Neurotrope Group and be treated equitably in all respects, including
in connection with deductibles, retentions, coinsurance and retrospective premium charges.

 

    31

     

    

 

(d)               Neurotrope shall not be liable to NBI for claims, or portions of claims, not reimbursed by insurers under any policy
for any reason, including coinsurance provisions, deductibles, quota share deductibles, self-insured retentions, bankruptcy or
insolvency of any insurance carrier(s), policy limitations or restrictions (including exhaustion of limits), any coverage disputes,
any failure to timely file a claim by any member of the Neurotrope Group or NBI or any defect in such claim or its processing.
In the event that insurable claims of both Neurotrope and NBI (or the members of their respective Groups) exist relating to the
same occurrence, the Parties shall jointly defend and waive any conflict of interest necessary to the conduct of the joint defense
and shall not settle or compromise any such claim without the consent of the other (which consent shall not be unreasonably withheld
or delayed subject to the terms and conditions of the applicable insurance policy). Nothing in this Section 7.01 shall be construed
to limit or otherwise alter in any way the obligations of the Parties, including those created by this Agreement, by operation
of Law or otherwise.

 

(e)               After the Distribution Date, to the extent that any claims have been duly reported on or before the Distribution
Date under the directors and officers liability insurance policies or fiduciary liability insurance policies (collectively, “D&O
Policies”) maintained by members of the Neurotrope Group, Neurotrope shall not, and shall cause the members of the Neurotrope
Group not to, take any action that would limit the coverage of the individuals who acted as directors or officers of NBI on or
prior to the Distribution Date under any D&O Policies maintained by the members of the Neurotrope Group. Neurotrope shall,
and shall cause members of the Neurotrope Group to, reasonably cooperate with the individuals who acted as directors and officers
of NBI on or prior to the Distribution Date in their pursuit of any coverage claims under such D&O Policies which could inure
to the benefit of such individuals. Neurotrope shall, and shall cause members of the Neurotrope Group to, allow NBI and its agents
and representatives, upon reasonable prior notice and during regular business hours, to examine and make copies of the relevant
D&O Policies maintained by Neurotrope and members of the Neurotrope Group pursuant to this Section 8.01(e). Neurotrope shall
provide, and shall cause other members of the Neurotrope Group to provide, such cooperation as is reasonably requested by NBI in
order for NBI to have in effect after the Distribution Date such new D&O Policies as NBI deems appropriate with respect to
claims reported after the Distribution Date. Except as provided in this Section 8.01(e), the Neurotrope Group may, at any time,
without liability or obligation to NBI, amend, commute, terminate, buy-out, extinguish liability under or otherwise modify any
 “occurrence-based” insurance policy or “claims-made-based” insurance policy (and such claims will be subject
to any such amendments, commutations, terminations, buy-outs, extinguishments and modifications); provided, however, that Neurotrope
will immediately notify NBI of any termination of any insurance policy.

 

    32

     

    

 

(f)                The parties shall use reasonable best efforts to cooperate with respect to the various insurance matters contemplated
by this Section 7.01.

 

ARTICLE
VIII

 

Intellectual Property

 

SECTION
8.01                      Consent To Use Trademarks And Duty To Cooperate. (a) NBI consents to the use and registration of the Neurotrope
Marks in the Neurotrope Business by Neurotrope and its Affiliates and their respective licensees. The consent in this Section 8.01(a)
includes consent to the Neurotrope Group’s and such licensees’ use and registration of names, trademarks and domain
names that include, in whole or in part, “Neurotrope Bioscience, Inc.” or the abbreviation “NBI”.

 

(b)               Neurotrope consents (on behalf of itself and each other member of the Neurotrope Group) to the use and registration
of the NBI Marks in the NBI Business by NBI and its Affiliates and their respective licensees. The consent in this Section 8.01(b)
includes consent to NBI’s and such licensees’ use and registration of names, trademarks and domain names that include,
in whole or in part, “NBI”.

 

(c)               NBI agrees that it will not oppose or petition to cancel, or assist another party in opposing or petitioning to cancel,
an application or registration by Neurotrope or its Affiliates or their respective licensees for a Neurotrope Mark that is consistent
with the use to which NBI has consented under this Agreement. Neurotrope agrees that it will not, and agrees to cause its Subsidiaries
not to, oppose or petition to cancel, or assist another party in opposing or petitioning to cancel, an application or registration
by NBI or its Affiliates or their respective licensees for a NBI Mark that is consistent with the use to which Neurotrope has consented
under this Agreement.

 

(d)               NBI hereby acknowledges Neurotrope’s right, title and interest in and to the Neurotrope Marks, and will not
in any way, directly or indirectly, do or cause to be done any act or thing contesting or in any way impairing or tending to impair
any part of such right, title and interest within the Neurotrope Business or with respect to goods or services provided in connection
with the Neurotrope Business. NBI agrees not to use, and agrees to cause its Subsidiaries not to use, the Neurotrope Marks, or
any names, trademarks or domain names that incorporate the Neurotrope Marks for any purpose.

 

In the event that Neurotrope
Marks prominently appear on any business or promotional materials used by NBI or its Affiliates within the NBI Business, NBI shall
remove and cease using such prominently appearing marks as soon as reasonably practical following the Distribution Date but in
any event within 90 days of the Distribution Date or, with respect to products for sale produced or published prior to the Distribution
Date on which any Neurotrope Mark prominently appears, within six months of the Distribution Date; provided that NBI shall promptly
arrange for the destruction of any such products for sale produced or published prior to the Distribution Date that remain unsold
following such six-month period and on which any Neurotrope Mark prominently appears.

 

    33

     

    

 

(e)               Neurotrope hereby acknowledges (on behalf of itself and each other member of the Neurotrope Group) NBI’s right,
title and interest in and to the NBI Marks, and will not in any way, directly or indirectly, do or cause to be done any act or
thing contesting or in any way impairing or tending to impair any part of such right, title and interest within the NBI Business
or with respect to goods or services provided in connection with the NBI Business. Neurotrope agrees not to use, and agrees to
cause its Subsidiaries not to use, the NBI Marks, except where the use is a use, otherwise than as a mark, of the party’s
individual name in its own business, or of the individual name of anyone in privity with such party, or of a term or device which
is descriptive of and used fairly and in good faith only to describe the goods or services of such party, or their geographic origin.
Without limiting the foregoing, neither Neurotrope nor its Affiliates shall use the name or mark NBI for any brand, mark, title
or any source identifiers.

 

In the event that NBI
Marks prominently appear on any business or promotional materials used by Neurotrope or its Affiliates within the Neurotrope Business,
Neurotrope shall remove and cease using such prominently appearing marks as soon as reasonably practical following the Distribution
Date but in any event within 90 days of the Distribution Date or, with respect to products for sale produced or published prior
to the Distribution Date on which any NBI Mark prominently appears, within six months of the Distribution Date; provided that Neurotrope
shall promptly arrange for the destruction of any such products for sale produced or published prior to the Distribution Date that
remain unsold following such six-month period and on which any NBI Mark prominently appears.

 

(f)                Each of Neurotrope and NBI believes its respective marks are sufficiently distinctive and different to ensure consumers
will not be confused as to source or sponsorship, and each agrees to employ its reasonable best efforts to use its respective marks
in a manner that does not cause actual confusion or a likelihood of confusion as to source or sponsorship of its respective goods
or services in its respective channels of trade. If, despite Neurotrope’s and NBI’s reasonable best efforts, such actual
confusion shall be brought to the attention of either such party, such parties agree to consult regarding steps to be taken to
mitigate or correct such actual confusion.

 

(g)               Each of Neurotrope and NBI shall be responsible for policing, protecting and enforcing its own trademarks, trade
names and service marks. Notwithstanding the forgoing, each of Neurotrope and NBI will promptly give notice to the other of any
known, actual or threatened, use or infringement that may cause consumers to be confused as to source or sponsorship between such
parties.

 

(h)               If a trademark office cites Neurotrope’s prior NBI formative trademark against NBI’s trademark application
for a NBI formative mark, or NBI’s prior NBI formative trademark against Neurotrope’s NBI trademark application, the
owner of the prior trademark will cooperate with the applicant and provide consent to the registration of the applied-for trademark,
provided the applied-for trademark application is not contrary to the terms of this Article IX.

 

    34

     

    

 

SECTION
8.02                      Domain Names. (a) At the expense of NBI, each of Neurotrope and NBI will use commercially reasonable efforts
to ensure the Domain Names in Schedule IX are: (i) listed with NBI or, on behalf of NBI, appropriate local counsel or other designated
agent of NBI as the owner/registrant; (ii) managed by NBI in a NBI-controlled registrar account; and (iii) placed on NBI domain
name servers, in each case within six months following the Distribution Date.

 

(b)               At the expense of NBI, NBI will use commercially reasonable efforts to identify and disable all uses of the Domain
Names identified in Schedule X within six months following the Distribution Date, and will notify Neurotrope that use has ceased.
Until the earlier of (x) the receipt of such notice from NBI and (y) the date that is six months following the Distribution Date,
Neurotrope will use commercially reasonable efforts to ensure that the Domain Names in Schedule X are: (i) listed with Neurotrope
or, on behalf of Neurotrope, appropriate local counsel or other designated agent of Neurotrope as the owner/registrant; (ii) managed
by Neurotrope in a Neurotrope-controlled registrar account; (iii) maintained as active registrations (i.e., not allowed to expire);
and (iv) not changed in any aspect from current usage.

 

(c)               Upon the earlier of (x) the receipt of the notice from NBI required under Section 9.02(b) and (y) the date that is
six months following the Distribution Date, Neurotrope will: (i) use commercially reasonable efforts to ensure that the Domain
Names identified in Schedule X are no longer publicly-facing by removing them from active domain name servers; and (ii) allow the
Domain Names identified in Schedule X to lapse; provided that, rather than allowing such Domain Names to lapse or following such
lapse, Neurotrope may, in its sole discretion, repurpose non-biopharmaceutical-focused Domain Names identified in Schedule X (e.g.,
[ ].com) for Neurotrope’s and its Affiliates’ own use.

 

SECTION
8.03                      Scope. The geographic scope of this Article VIII shall be worldwide.

 

SECTION
8.04                      Licenses; Assignments. Any license, assignments or other transfer of rights in the Neurotrope Marks, the NBI
Marks or the Domain Names to a third party shall be accompanied by the restrictions provided in this Article VIII.

 

ARTICLE
IX

 

Further Assurances and Additional Covenants

 

SECTION
9.01                      Further Assurances and Additional Covenants. (a) In addition to the actions specifically provided for elsewhere
in this Agreement, each of the Parties shall, subject to Section 4.03, use reasonable best efforts, prior to, on and after the
Distribution Date, to take, or cause to be taken, all actions, and to do, or cause to be done, all things, reasonably necessary,
proper or advisable under applicable Laws and agreements to consummate and make effective the transactions contemplated by this
Agreement.

 

(b)               Without limiting the foregoing, prior to, on and after the Distribution Date, each Party shall cooperate with the
other Party, without any further consideration, but at the expense of the requesting Party, (i) to execute and deliver, or use
reasonable best efforts to execute and deliver, or cause to be executed and delivered, all instruments, including any instruments
of conveyance, assignment and transfer as such Party may reasonably be requested to execute and deliver by the other Party, (ii)
to make, or cause to be made, all filings with, and to obtain, or cause to be obtained, all Consents of any Governmental Authority
or any other Person under any permit, license, agreement, indenture or other instrument, (iii) to obtain, or cause to be obtained,
any Governmental Approvals or other Consents required to effect the Spin-Off and (iv) to take, or cause to be taken, all such other
actions as such Party may reasonably be requested to take by the other Party from time to time, consistent with the terms of this
Agreement and the Ancillary Agreements, in order to effectuate the provisions and purposes of this Agreement and any transfers
of Assets or assignments and assumptions of Liabilities hereunder and the other transactions contemplated hereby.

 

    35

     

    

 

(c)               On or prior to the Distribution Date, Neurotrope and NBI, in their respective capacities as direct and indirect shareholders
of their respective Subsidiaries, shall each ratify any actions that are reasonably necessary or desirable to be taken by NBI or
any other Subsidiary of Neurotrope, as the case may be, to effectuate the transactions contemplated by this Agreement.

 

(d)               Prior to the Distribution, if either Party identifies any commercial or other service that is needed to ensure a
smooth and orderly transition of its business in connection with the consummation of the transactions contemplated hereby, and
that is not otherwise governed by the provisions of this Agreement or any Ancillary Agreement, the Parties will cooperate in determining
whether there is a mutually acceptable arm’s-length basis on which the other Party will provide such service.

 

(e)               Neurotrope and NBI shall settle the Payables Transactions in accordance with Schedule I. As soon as reasonably possible
following the Distribution Date, the Parties agree to determine and settle the final amounts of the Payables Transactions to the
extent such amounts have not previously been settled.

 

ARTICLE
X

 

Termination

 

SECTION
10.01                   Termination. This Agreement may be terminated by Neurotrope at any time, in its sole discretion, only upon
the abandonment of the Merger and prior to the Distribution.

 

SECTION
10.02                    Effect of Termination. In the event of any termination of this Agreement prior to the Distribution, neither
Party (nor any of its directors or officers) shall have any Liability or further obligation to the other Party under this Agreement
or the Ancillary Agreements.

 

    36

     

    

 

ARTICLE
XI

 

Miscellaneous

 

SECTION
11.01                     Counterparts; Entire Agreement; Corporate Power.

 

(a)               This
Agreement may be executed in one or more counterparts, all of which counterparts shall be considered one and the same agreement,
and shall become effective when one or more counterparts have been signed by each Party and delivered to the other Party. This
Agreement may be executed by facsimile or PDF signature and a facsimile or PDF signature shall constitute an original for all purposes.

 

(b)               This Agreement, the Ancillary Agreements and the Appendices, Exhibits and Schedules hereto and thereto contain the
entire agreement between the Parties with respect to the subject matter hereof and supersede all previous agreements, negotiations,
discussions, writings, understandings, commitments and conversations with respect to such subject matter, and there are no agreements
or understandings between the Parties with respect to the subject matter hereof other than those set forth or referred to herein
or therein.

 

(c)               Neurotrope represents on behalf of itself and each other member of the Neurotrope Group, and NBI represents on behalf
of itself, as follows:

 

(i)             each such Person has the requisite corporate or other power and authority and has taken all corporate or other action
necessary in order to execute, deliver and perform each of this Agreement and each Ancillary Agreement to which it is a party and
to consummate the transactions contemplated hereby and thereby; and

 

(ii)            this Agreement and each Ancillary Agreement to which it is a party has been (or, in the case of any Ancillary Agreement,
will be on or prior to the Distribution Date) duly executed and delivered by it and constitutes, or will constitute, a valid and
binding agreement of it enforceable in accordance with the terms thereof.

 

SECTION
11.02                     Governing
Law; Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the Laws of the State of New York,
regardless of the Laws that might otherwise govern under applicable principles of conflicts of laws thereof. Each Party irrevocably
consents to the exclusive jurisdiction, forum and venue of the Commercial Division of the Supreme Court of the State of New York,
New York County and the United States District Court for the Southern District of New York over any and all claims, disputes,
controversies or disagreements between the Parties or any of their respective Subsidiaries, Affiliates, successors and assigns
under or related to this Agreement or any document executed pursuant to this Agreement or any of the transactions contemplated
hereby or thereby.

 

SECTION
11.03                    Assignability.
Neither this Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned, in whole or in
part, by operation of law or otherwise by either Party without the prior written consent of the other Party. Any purported assignment
without such consent shall be void. Subject to the preceding sentences, this Agreement will be binding upon, inure to the benefit
of, and be enforceable by, the Parties and their respective successors and assigns. Notwithstanding the foregoing, either Party
may assign this Agreement without consent in connection with (a) a merger transaction in which such Party is not the surviving
entity and the surviving entity acquires or assumes all or substantially all of such Party’s Assets, or (b) the sale of
all or substantially all of such Party’s Assets; provided, however, that the assignee expressly assumes in writing all of
the obligations of the assigning Party under this Agreement, and the assigning Party provides written notice and evidence of such
assignment and assumption to the non-assigning Party. No assignment permitted by this Section 12.03 shall release the assigning
Party from liability for the full performance of its obligations under this Agreement.

 

    37

     

    

 

SECTION
11.04                    Third-Party
Beneficiaries. Except for the indemnification rights under this Agreement of any Neurotrope Indemnitee or NBI Indemnitee in
their respective capacities as such, (a) the provisions of this Agreement are solely for the benefit of the Parties hereto and
are not intended to confer upon any Person except the Parties hereto any rights or remedies hereunder and (b) there are no third-party
beneficiaries of this Agreement and this Agreement shall not provide any third person with any remedy, claim, liability, reimbursement,
cause of action or other right in excess of those existing without reference to this Agreement.

 

SECTION
11.05                    Notices.
All notices or other communications under this Agreement shall be in writing and shall be deemed to be duly given when (a) delivered
in person, (b) on the date received, if sent by a nationally recognized delivery or courier service or (c) upon the earlier of
confirmed receipt or the fifth business day following the date of mailing if sent by registered or certified mail, return receipt
requested, postage prepaid, addressed as follows:

 

If to Neurotrope (prior
to Closing), to:

 

Neurotrope, Inc.

1185 Avenue of the
Americas, 3rd Floor

New York, New York,
10036

Attn: General Counsel

 

with a copy to:

 

Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C.

666 Third Avenue

New York, NY 10017

Attn: Kenneth Koch

 

If to Neurotrope (after
Closing), to:

 

Metuchen Pharmaceuticals,
LLC

200 U.S. 9, Ste 500

Manalapan Township,
NJ 07726

Attn: John Shulman

 

With a copy to:

Morgan Lewis &
Bockius LLP

1111 Pennsylvania Ave
NW

Washington, DC 20004

Attn: Andrew Ray

 

    38

     

    

 

If to NBI, to:

 

Neurotrope Bioscience,
Inc.

1185 Avenue of the
Americas, 3rd Floor

New York, New York,
10036

Attn: Chief Financial
Officer

 

Either Party may, by
notice to the other Party, change the address to which such notices are to be given.

 

SECTION
11.06                    Severability.
If any provision of this Agreement or the application thereof to any Person or circumstance is determined by a court of competent
jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof, or the application of such provision to Persons
or circumstances or in jurisdictions other than those as to which it has been held invalid or unenforceable, shall remain in full
force and effect and shall in no way be affected, impaired or invalidated thereby, so long as the economic or legal substance
of the transactions contemplated hereby is not affected in any manner materially adverse to either Party. Upon any such determination,
any such provision, to the extent determined to be invalid, void or unenforceable, shall be deemed replaced by a provision that
such court determines is valid and enforceable and that comes closest to expressing the intention of the invalid, void or unenforceable
provision.

 

SECTION
11.07                   Publicity. Each of Neurotrope and NBI shall consult with the other prior to issuing, and shall, subject to
the requirements of Section 6.08, provide the other Party the opportunity to review and comment upon, any press releases or other
public statements in connection with the Spin-Off or any of the other transactions contemplated hereby and prior to making any
filings with any Governmental Authority or national securities exchange with respect thereto (including the Form S-1, the Parties’
respective Current Reports on Form 8-K to be filed on the Distribution Date, the Parties’ respective Quarterly Reports on
Form 10-Q filed with respect to the fiscal quarter during which the Distribution Date occurs, or if such quarter is the fourth
fiscal quarter, the Parties’ respective Annual Reports on Form 10-K filed with respect to the fiscal year during which the
Distribution Date occurs (each such Quarterly Report on Form 10-Q or Annual Report on Form 10-K, a “First Post-Distribution
Report”)). Each Party’s obligations pursuant to this Section 11.07 shall terminate on the date on which such Party’s
First Post-Distribution Report is filed with the Commission.

 

SECTION
11.08                    Expenses.
Except as expressly set forth in this Agreement or in any Ancillary Agreement, all third-party fees, costs and expenses paid or
incurred in connection with the Spin-Off will be paid by the Party incurring such fees or expenses, whether or not the Distribution
is consummated, or as otherwise agreed by the Parties. For the avoidance of doubt, Neurotrope shall bear the costs and expenses
directly related to the mailing of the Form S-1 to Neurotrope shareholders and the fees and expenses of the Agent in connection
with the Distribution, and NBI shall bear the fees and expenses of Toppan Printing Co., Ltd. in connection with the Spin-Off,
the fees and expenses of any accounting or legal advisors retained by NBI, the fees of B. Riley Financial Inc. in connection with
the application and listing of the NBI Common Stock and the fees of the Commission in connection with any filing by NBI.

 

    39

     

    

 

SECTION
11.09                    Headings. The article, section and paragraph headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this Agreement.

 

SECTION
11.10                    Survival of Covenants. Except as expressly set forth in this Agreement, the covenants in this Agreement and
the liabilities for the breach of any obligations in this Agreement shall survive the Spin-Off and shall remain in full force and
effect.

 

SECTION
11.11                    Waivers of Default. No failure or delay of any Party (or the applicable member of its Group) in exercising
any right or remedy under this Agreement or any Ancillary Agreement shall operate as a waiver thereof, nor shall any single or
partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, or any
course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. Waiver by any Party
of any default by the other Party of any provision of this Agreement shall not be deemed a waiver by the waiving Party of any subsequent
or other default.

 

SECTION
11.12                    Specific Performance. Subject to Section 4.03 and notwithstanding the procedures set forth in Article IX,
in the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions of this Agreement,
the affected Party shall have the right to specific performance and injunctive or other equitable relief of its rights under this
Agreement, in addition to any and all other rights and remedies at law or in equity, and all such rights and remedies shall be
cumulative. The other Party shall not oppose the granting of such relief on the basis that money damages are an adequate remedy.
The Parties agree that the remedies at law for any breach or threatened breach hereof, including monetary damages, are inadequate
compensation for any loss and that any defense in any action for specific performance that a remedy at law would be adequate is
waived. Any requirements for the securing or posting of any bond with such remedy are waived.

 

SECTION
11.13                    Amendments. No provisions of this Agreement shall be deemed waived, amended, supplemented or modified by any
Party, unless such waiver, amendment, supplement or modification is in writing and signed by the authorized representative of each
Party.

 

SECTION
11.14                    Interpretation. Words in the singular shall be held to include the plural and vice versa and words of one
gender shall be held to include the other gender as the context requires. The terms “hereof,” “herein”
and “herewith” and words of similar import, unless otherwise stated, shall be construed to refer to this Agreement
as a whole (including all of the schedules hereto) and not to any particular provision of this Agreement. Article, Section or Schedule
references are to the articles, sections and schedules of or to this Agreement unless otherwise specified. Any capitalized terms
used in any Schedule to this Agreement or to any Ancillary Agreement but not otherwise defined therein shall have the meaning as
defined in this Agreement or the Ancillary Agreement to which such Schedule is attached, as applicable. Any reference herein to
this Agreement, unless otherwise stated, shall be construed to refer to this Agreement as amended, supplemented or otherwise modified
from time to time, as permitted by Section 11.13. The word “including” and words of similar import when used in this
Agreement shall mean “including, without limitation,” unless the context otherwise requires or unless otherwise specified.
The word “or” shall not be exclusive.

 

    40

     

    

 

IN WITNESS WHEREOF,
the Parties have caused this Separation and Distribution Agreement to be executed by their duly authorized representatives.

 

	 	Neurotrope, Inc.
	 	 	 
	 	By	 /s/ Joshua Silverman
	 	Name: Joshua Silverman
	 	Title: Director and Chairman of the Board
	 	 	 
	 	Neurotrope Bioscience, Inc.
	 	 	 
	 	By	/s/ Robert Weinstein
	 	Name: Robert Weinstein
	 	Title: Chief Financial Officer

 

    41

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]